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ABSTRACT OF DISSERTATION

ROLE OF OXIDIZED EXTRACELLULAR VESICLES AS EARLY BIOMARKERS
AND INFLAMMATORY MEDIATORS IN CHEMOTHERAPY-INDUCED
NORMAL TISSUE INJURY
Significant advances in the efficacy of cancer therapy have been
accompanied by an escalation of side effects that result from therapy-induced
injury to normal tissues. Patients with high grade cancer or metastasis are often
treated with chemotherapy, 50% of which are associated with reactive oxygen
species generation and cellular oxidative stress. Heart is the normal tissue most
susceptible to chemotherapy-induced oxidative stress and heart disease is the
most common leading cause of death in cancer survivors. However, early and
sensitive biomarkers to identify heart disease are still lacking. Extracellular
vesicles (EVs) are released from cells during oxidative stress and send oxidized
proteins into the circulation as a compensatory mechanism that prevents cellular
proteotoxicity. Thus, the protein contents of EVs released during the predegeneration stage reveal that oxidative stress is occurring early in the damaged
tissue. Using a mouse model of doxorubicin (DOX)-induced cardiac injury, we
demonstrated that EVs can be used as an early diagnostic tool for tissue injury
as they are oxidatively modified with 4-hydroxynonenal and contain tissue
specific proteins—glycogen phosphorylase brain/heart, muscle, and liver
isoforms—that indicate their origins. These biomarkers increased early, before
the changes of conventional biomarkers occurred.
EVs also mediate intercellular communication by transferring bioactive
molecules between cells. In the cell culture system, EVs play an important role in
oxidative stress response by inducing macrophage polarization. EVs from
cardiomyocytes promoted both proinflammatory (M1) and anti-inflammatory (M2)
macrophage polarization evidenced by higher pro- and anti-inflammatory
cytokines and nitric oxide generation, as well as mitochondrial oxidative
phosphorylation suppression and glycolysis enhancement. In contrast, EVs from
the hepatocytes supported anti-inflammatory macrophage (M2) by enhancing
oxidative phosphorylation and anti-oxidant proteins. DOX promoted the
immunostimulatory effects of cardiomyocyte EVs but not hepatocyte EVs. The
differential functions of EVs on macrophage phenotype switching are due to their

different effects on Thioredoxin 1 redox state, which regulates activities of redox
sensitive transcription factors NFκB and Nrf-2. Our findings shed light on the role
of EVs as a redox active mediator of immune response during chemotherapy.
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CHAPTER 1. INTRODUCTION
Improved cancer treatment has raised the five-year survival rate of adult
cancer patients from 49% in the late 1970s to 69% between 2005 and 2011. In
childhood cancer patients, the survival rate is even better, having improved from
58% in the 1970s to 83% by 2011. However, these gains have been
accompanied by increased risks. The longer a cancer patient lives, the greater
the possibility that complications from cancer treatment will occur. Complications
can arise, in part, from oxidative stress-induced damage to noncancerous tissue,
which decreases the quality of life of cancer survivors. Treatment-related side
effects such as cardiotoxicity are the third leading cause of death in adult and
childhood cancer survivors. Recurrence and secondary tumors are the first and
second leading causes of death, respectively [1]. The American Cancer Society
has predicted that there will be 20.3 million long-term cancer survivors in the U.S.
by 2026. This immense number of survivors will necessitate an emphasis on
preventive strategies that preserve normal tissues while killing cancer cells.
Currently, 215 drugs have been approved by the FDA to treat cancer. At
least fifty percent of them can induce oxidative stress, among them Doxorubicin
(DOX) is the best-known cause of late-onset cardiomyopathy in cancer patients.
Oxidative stress is a well-accepted mechanism of DOX-induced cardiotoxicity.
Excessive reactive oxygen species (ROS)/ reactive nitrogen species (RNS) that
reaches the threshold of antioxidant capacity of the cells, as well as the
accumulation of oxidized biomolecules that overwhelm the biomolecular quality
controls of cells, cause cytotoxicity to cancer and normal cells. To combat
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against oxidative stress-induced cytotoxicity, the cells have evolved several
pathways to remove oxidized toxic molecules including proteasome-mediated
degradation and autophagy, as well as removing the toxic molecules in the form
of extracellular vesicles.
Extracellular vesicles (EVs) are membranous encapsulated structures that
are released from almost all cell types. EVs are heterogeneous in size, contents
and biogenesis. They are generally classified into 3 types based on the
biogenesis: exosomes, microvesicles, and apoptotic bodies. EVs serve as a
compensatory mechanism to remove oxidized molecules under oxidative stress
condition to maintain cellular homeostasis. The oxidized molecules of EVs are
stable in the environment due to protective lipid bilayer making them potential
biomarkers for oxidative stress-related diseases

including DOX-induced

cardiotoxicity.
EVs also serve as a vehicle that transfers bioactive molecules between
cells, thus mediating cell-cell communication during cellular stress. Innate
immune response plays a crucial role in the progression of heart failure.
However, how cardiomyocytes communicate with immune cells during DOXinduced cardiotoxicity is still unclear. The overall goal of this study is to
investigate the role of EVs as biomarkers and mediators of chronic inflammation
in DOX-induced cardiomyopathy. Understanding of cellular communication
during chronic inflammatory processes in DOX-induced cardiomyopathy will help
develop new therapeutic approaches for treatment and prevention of this
disease.

2

Doxorubicin-Induced Cardiomyopathy
DOX is one of the most effective anticancer treatments that has a broad
range of therapeutic activities against both hematological and solid tumors,
including breast cancer, ovarian cancer, soft-tissue and bone sarcoma, nonHodgkin’s and Hodgkin’s lymphoma, and multiple myeloma [2]. However, DOX
carries

a

severe

chronic

side

effect

known

as

doxorubicin-induced

cardiomyopathy, which eventually leads to heart failure. The risk of heart failure
development increases rapidly when the patients receive a cumulative dose of
DOX > 550 mg/m2 [3]. Evidence of heart failure can present years after cessation
of the treatment [4]. Doxorubicin-induced cardiomyopathy has a poor prognosis
with the mortality rate as high as 61% [5]. Pathologic finding from myocardial
biopsy from patients with doxorubicin-induced cardiomyopathy is characterized
by loss of myofibrils and cytoplasmic vacuolization [4]. The risk to develop DOXinduced cardiomyopathy is difficult to identify because individual sensitivity to
DOX is diverse and there is no ideal monitoring test to predict late onset
cardiomyopathy. Most of the biomarkers used in the screening for cardiovascular
disease development such as cardiac troponin T and B-type natriuretic peptide
can be detected after cardiac injury and neurohormonal changes [6], which may
occur too late to begin the treatment. To prevent cardiac outcome promptly,
identification of individual risk and early diagnosis by sensitive non-invasive
biomarkers are needed.
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Mechanisms of Doxorubicin-Induced Cardiomyopathy
Decades-long research has explored the mechanisms by which DOX
causes cardiomyopathy via multiple pathways [5]. DOX-induced cardiomyopathy
engages not only cell death related signaling pathway in cardiomyocyte itself but
also the intercellular communication leading to tissue inflammation and
maladaptive remodeling.
The generation of ROS and RNS is an initial event of DOX-induced
cardiac tissue injury. Mitochondria are the major subcellular organelles affected
by DOX since DOX has 300-1000 fold higher affinity for binding to cardiolipin, a
major component of inner mitochondrial membrane, compared to other anionic
phospholipids [7]. The redox cycling of quinone-DOX to the semiquinone radical
formed by diverting one electron from NADH dehydrogenase at complex I and
donating the electron to molecular oxygen gives rise to superoxide radical (O2•-)
formation [8]. O2•- can also be generated by other enzymatic reactions such as
cytochrome P450 reductase, xanthine oxidase, and uncoupled nitric oxide
synthase, as well as non-enzymatic reactions from redox cycling of DOX-Fe3+
complex [9].
Manganese superoxide dismutase (MnSOD) is the major enzyme
responsible for mitochondrial O2•- removal, yielding hydrogen peroxide (H2O2) as
a product. H2O2 can be further detoxified by catalase and glutathione peroxidase.
However, excessive superoxide radicals can react with other ROS and RNS such
as H2O2 and nitric oxide radical (NO) to form more highly reactive ROS/RNS.
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Aconitase is a tricarboxylic acid cycle enzyme responsible for catalyzing
the conversion of aconitate to isocitrate [10]. Aconitase contains iron-sulfur
clusters that are sensitive to O2•- inactivation, which results in the release of Fe2+
from the enzyme [11]. O2•- can also induce the release of Fe2+ from ferritin, an
intracellular iron storage protein [12]. Fe2+ further catalyzes the interaction of O2•with H2O2 leading to hydroxyl radical (OH) generation. The interaction of O2•with NO generates peroxinitrite (ONOO-). Both ONOO- and OH are highly
reactive and can damage biomolecules such as lipids, proteins and nucleic acids.
Unsaturated fatty acids, major components of the cellular membrane,
contain carbon-carbon double bonds making them susceptible to ROS/RNS
attack. Two major ⍵6 lipid peroxidation products derived from nonenzymatic
ROS/RNS attack are malondialdehyde (MDA) and 4-hydroxynonenal (4HNE).
Among the major lipid peroxidation products, 4HNE is the most toxic. 4HNE
rapidly reacts with thiols and the amino groups of amino acids leading to 4HNE
protein adduction. It has been shown that protein-bound 4HNE forms early after
DOX treatment. In cardiac mitochondria, protein-bound 4HNE forms as early as 3
hours following treatment and rises to its highest level at 6 hours post- treatment.
An increase in 4HNE-bound proteins occurs in mitochondria prior to occurring in
cytoplasm and nucleus [13]. A high level of 4HNE leads to inactivation of the
adducted proteins. Our recent study showed that during DOX treatment, 4HNEadducted proteins in heart tissues that are involved in the electron transport
chain,

such

as

succinate

dehydrogenase

A

(SDHA),

dihydrolipoamide

dehydrogenase (DLD), ATP synthase subunit β (ATP5B), and NADH
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dehydrogenase [ubiquinone] iron-sulfur protein 2 (NDUFS2), led to mitochondrial
respiratory dysfunction and a shift of energy production to glycolysis [14].
Furthermore, 4HNE adduction to mitochondrial protein, as in mitochondrial
apoptotic inducing factor 2 (AIFM2), can alter the protein function from
oxidoreductase to pro-apoptotic protein leading to cardiomyocyte cell death [15].
Cellular Mechanisms to Maintain Homeostasis against Oxidative Stress
Cells contain several protein quality control (PQC) mechanisms that
maintain physiological homeostasis against highly toxic oxidized protein
accumulation. Those mechanisms involve protein unfolding via endoplasmic
reticulum, intracellular protein degradation via the ubiquitin-proteasome pathway,
autophagy-lysosomal pathways, and extracellular vesicles release [16-18]. PQC
is highly regulated by the cellular redox status. A growing body of evidence
shows that DOX affects PQC in cardiomyocytes leading to the accumulation of
oxidized proteins and eventually cell death [18,19].
Protein Unfolding System
Protein oxidative modification involves a disturbance of protein folding
resulting in aberrant protein conformations that affect protein function, stability
and solubility [20]. Protein unfolding occurs in the organelle Endoplasmic
Reticulum (ER) where it serves as a first- line response against toxic oxidized
proteins. Protein unfolding is initiated by stress-sensor proteins on the ER
membrane, activating transcription factor 6 (ATF6), inositol-requiring enzyme 1
(IRE1), and protein kinase RNA-like ER kinase (PERK). ATF6 and IRE1
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activation initiates an adaptive response by upregulating 78 kDa glucose-related
protein (GRP78), an ER chaperone protein responsible for regulating protein
folding. PERK activation regulates negative feedback control by inhibiting protein
translation and thus alleviating ER workload [21]. However, excessive ER stress
initiates the apoptotic pathway mediated by caspase-12, c-Jun NH2-terminal
kinase (JNK) and C/EBP homologous protein (CHOP). A histological study of
endomyocardial biopsies from patients experiencing DOX-induced cardiotoxicity
revealed extensive ER dilation [22], suggesting that ER stress is a major
mechanism of DOX-induced cardiotoxicity. Recently, a study in mice revealed
that DOX activated ATF6 and IRE1 but failed to upregulate GRP78 gene
expression leading to a shift from ER adaptive stress response to the apoptosis
response [23].
Ubiquitin-Proteasome System (UPS)
The Ubiquitin-proteasome system (UPS) is responsible for removing
cytosolic oxidized proteins, which are ubiquitinated by three classes of enzymes
working in concert. Ubiquitin activation enzyme (E1) activates and transfers
ubiquitin to ubiquitin conjugation enzyme (E2). Ubiquitin ligase (E3) positions the
target substrate in order to transfer ubiquitin from E2 to lysine residues of the
substrate. The polyubiquitinated proteins at lysines are subsequently recognized
and degraded by the 26S proteasome. Alternately, oxidized protein without
ubiquitination can be degraded by the 20S proteasome. UPS is highly regulated
by the cellular redox status. Mild oxidative stress upregulates the ubiquitination
machinery and proteasome activity. However, severe oxidative stress inhibits
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proteasome activity yet it spares the ubiquitination systems. This leads to the
accumulation of oxidized-polyubiquitinated proteins [24]. DOX is known to cause
massive protein oxidation and ubiquitination. However, the role of DOX in UPS
remains controversial. A study of H9c2 cardiomyoblasts treated with 3 µM DOX
for 24 hours and tumor bearing mice treated with a cumulative dose of DOX at 20
mg/kg revealed that DOX inhibits proteasome activity while it stimulates protein
ubiquitination by increasing E3 ligase expression [25]. However, another study
using a lower concentration of the therapeutic dose (0.1-5 µM) found that DOX
upregulates E3 ligase, the C-terminal of heat shock protein cognate 70interacting protein (CHIP), and heat shock protein 70, as well as activates the
20S proteasome [26]. Nevertheless, proteasome function relies heavily on
protein unfolding for the translocation of the protein into the proteasome lumen to
occur [27]. DOX levels that causes extensive oxidized protein misfolding and
aggregration might compromise the UPS system despite the enhanced
proteasome activity.
Autophagy
Autophagy, literally self-digestion, contributes to degradation of cytosolic
protein aggregates and dysfunctional organelles. Damaged components of
autophagy are trafficked to lysosome for degradation. This process can be
mediated by three different pathways; macroautophagy, microautophagy, and
chaperone-mediated autophagy (CMA). Macroautophagy is characterized by
sequestration of the cargoes by double-membrane structures, which progress to
autophagosome formation and subsequently fusion to lysosome for degradation.
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The process of macroautophagy initiates with the activation of the unc-51-like
autophagy activating kinase 1 (ULK-1) complex, which further activates Beclin-1
and the vesicle-mediated vacuolar protein sorting (VPS34) complex—the two
proteins that mediate phagophore formation. Subsequently, autophagy- related
gene (ATG) proteins 5, 12, and 16 are recruited to the phagophore membrane
and extend the phagophore. The cytosolic form of microtubule-associated protein
1A/1B-light chain 3 (LC3-I) is then lipidated with phosphatidylethanolamine to
form LC3-II, which is also recruited to the phagophore membrane. The
ubiquitinated damaged protein substrate, along with p62/SQSTM1, interacts with
LC3-II, all of which are then engulfed by phagophore to form an autophagosome.
The final process is the fusion of autophagosome with lysosome and the
degradation of autophagosome cargoes by lysosomal enzymes. Microautophagy
directly engulfs the cytosolic component by invagination of lysosomal membrane.
CMA requires heat shock-cognate protein of 70 KDa (HSC70) to recognize
proteins that contain the pentapeptide sequence KFERQ. HSC70- bound
KFERQ-containing protein then binds to lysosome-associated membrane protein
type 2A (LAMP-2A) on the lysosomal membrane, which translocates the target
protein into lysosomal lumen for degradation [28]. Blocking autophagic flux leads
to an accumulation of oxidized proteins and organelles that are toxic to the cells.
DOX has been shown to disrupt macroautophagy and CMA. The process
of autophagy dysregulation following DOX exposure has been extensively
reviewed [18,29,30]. DOX promotes autophagosome formation by increasing the
LC3-II level and ATGs protein expression [31]. The DOX-derived lipid
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peroxidation product 4HNE is also a potent activator of aldehyde-induced
autophagy [32]. Our previous study found that p53 is a key player that drives
JNK1-mediated autophagosome formation and p53 knockout mice are protected
from DOX-induced oxidative stress in mitochondria [33]. Recently, Bartlett and
colleagues reported that DOX inhibits vacuolar ATPase (VATPase), a proton
pump on the lysosomal membrane that maintains the acidic pH required for
lysosomal degradation. Furthermore, the same group also found that DOX
suppresses the expression of transcription factor EB, which is a key protein
governing lysosomal content and function [34]. These lysosome- blocking effects
lead to an accumulation of undegraded autolysosomes resulting in additional
ROS production and cardiac injury [35].
Mitophagy
Healthy mitochondria are required for ATP generation that supports
cardiac contractility. Mitophagy, which has a major influence on the quality of
mitochondria, relies on autophagy machinery. Two mitophagy pathways have
been described in cardiomyocytes— (1) the Phosphatase and tensin homologinduced putative kinase 1 (PINK1)/ E3 ubiquitin-protein ligase Parkin-mediated,
and (2) the BCL2 interacting protein 3-like (Bnip3L)/Nip3-like protein X (NIX)mediated pathways. The PINK1/Parkin pathway is triggered by mitochondrial
membrane

depolarization,

which

promotes

the

stability

of

PINK1,

a

serine/threonine kinase located on the mitochondrial outer membrane. PINK1
then attracts and binds to Parkin, which subsequently ubiquitinates proteins
responsible

for

mitochondrial

movement

10

cessation

and

mitochondrial

fragmentation maintenance. This ubiquitination process targets the damaged
mitochondria for lysosome degradation [36]. In contrast to the PINK1/Parkin
pathway, the Bnip3L/NIX pathway does not require mitochondrial membrane
depolarization but involves phosphorylation near the LIR motif of Bnip3L, which
makes it a docking site for LC3-II on autophagosomal membrane.
DOX affects PINK1/Parkin and Bnip3L/NIX mitophagy in different ways.
DOX suppresses PINK1/Parkin mitophagy by reducing PINK1 mitochondrial
translocation. Hoshino and colleagues reported that DOX-induced p53 activation
leads to the interaction and sequestration of PINK-1 by p53 [37]. In contrast,
DOX enhances Bnip3L/NIX mitophagy by inducing mitochondrial translocation of
Bnip3L, which leads to mitochondrial depolarization and Parkin recruitment [38].
However, cytosolic sequestration of PINK1, the Parkin partner, may blunt the
effect of the Bnip3L pathway. Although DOX can either suppress or activate the
upstream process of mitophagy, lysosome dysfunction caused by DOX, which
blocks the end process of mitophagy, could lead to the retention of undigested
damaged mitochondria.
Extracellular Vesicles
“Extracellular vesicles” is a general term that applies to membranous
vesicles released from cells into extracellular space. EVs are composed of a lipid
bilayer that encapsulates a variety of biomolecules, including proteins, DNAs,
RNAs, and carbohydrates, as well as subcellular organelles such as
mitochondria [39,40]. EV cargoes are resistant to enzymatic degradation owing
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to the lipid bilayer shelter. EV stability has been evaluated in various conditions.
Serum EVs are stable up to 24 hours at room temperature, 1 week at 4 °C, and
fewer than 3 freeze-thaw cycles. Prolonged storage beyond the indicated time
period and too many freeze-thaw cycles will cause EV rupture and content
leakage [41]. Milk-derived EVs can withstand acidic pH (pH = 2.0), a short boiling
temperature (105 °C, 15 minutes), and snap freezing in liquid nitrogen. However,
the same conditions significantly degrade cell-derived EVs by 90%, 90% and
70%, respectively [42].
Despite EV stability ex vivo, the half-life of EVs in vivo is only 2 minutes
due to a rapid clearance by interaction with other recipient cells [43]. The ability
of EVs released from one cell to interact with other cells makes EVs a mediator
of cell-cell communication. EVs express docking proteins on their surface that
could be recognized by the recipient cells. The message from one cell to the
other could be achieved by interaction of EVs with cognate receptors on recipient
cell surface, fusion of EV membrane with recipient plasma membrane, or
phagocytosis and delivery of EV contents into the recipient cytosol [44].
EVs are heterogeneous in size, content and biogenesis. Exosomes are
the smallest EVs (50-100 nm) and originate from invagination of late endosomal
membranes forming multiple intraluminal vesicles (ILVs) called multivesicular
bodies (MVB). Those ILVs become exosomes when they are released by the
fusion of MVB membrane with plasma membrane. Microvesicles (200-1000 nm)
are formed by outward budding of plasma membranes. Apoptotic bodies (>1000
nm) are generated by apoptotic cell fragmentation [45].
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Exosome Biogenesis
MVB formation requires machinery that not only sorts proteins to the
endosomal membrane but also sorts proteins involved in changing membrane
curvature and vesicle scission. Endosomal sorting complexes required for
transports (ESCRTs: ESCRT-0 to ESCRT-III) are the best-known protein
complexes that govern protein loading into exosomes. ESCRT-0 binds to
ubiquitinated protein cargo and distributes it to MVB membranes. ESCRT-I
associates with ESCRT-0 and ubiquitinated proteins to assist with the membrane
translocation. ESCRT-II is a bridge that connects ESCRT-I to ESCRT-III, which is
key to membrane budding and vesicle formation. In the final step, vacuolar
protein sorting-associated protein 4 (VPS4) complex dissociates ESCRT-III
thereby recyling the ESCRT machineries [46]. However, ESCRT is dispensable
to MVB generation in some cell types. For example, oligodendroglial cells utilize
neutral sphingomyelinase to generate ceramide forming lipid-raft microdomain for
endosomal membrane budding [47]. In lung cancer cell lines after radiation, p53
is activated leading to transcription of tumor suppressor activated pathway-6
(TSAP6), a transmembrane protein involved in MVB formation [48,49]. The p53dependent MVB formation explains how DNA damage promotes exosome
release.
Protein sorting into MVB can be alternatively mediated by HSC70, a key
protein that binds to oxidized protein in CMA. However, the interactions of
HSC70 with the endosomal membrane and the lysosomal membrane are
different. HSC70 relies on the electrostatic force from its basic residues to attach
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to acidic phospholipids on the cytosolic part of endosomal membrane rather than
binding to LAMP2A [28].
Exosome biogenesis and autophagy are closely related. MVB cargoes are
at a crossroads that could be sorted for degradation by lysosome fusion, or be
released by plasma membrane fusion. The final destination of MVB is governed
by the Rab family of small GTPases. Rab7 directs MVB to fuse with lysosomes,
while Rab27A directs it to fuse with plasma membrane [50,51]. Thus, if one
pathway is blocked, the cargo will pass to the other pathway. For example,
ESCRT depletion in Caenorhabditis elegans enhances autophagic flux, which
rescues cells from abnormal endosome buildup [52]. Conditions that promote
autophagy divert MVB to the lysosome rather than the plasma membrane, thus
inhibiting exosome release [53]. On the other hand, autophagy defects, such as
in neurogenerative diseases, promote release of oxidized protein aggregates via
exosomes [54]. In addition, chemical or genetic inhibition of the phosphoinositide
kinase PIKfyve, a key enzyme in membrane autophagy trafficking, promotes the
release of exosomes that contain proteins related to autophagy [55].
Microvesicles (MVs) Biogenesis
Microvesicles are EVs that originate from the plasma membrane. The
formation of microvesicles involves rearrangement of plasma membrane
phospholipids and reorganization of the underlying cytoskeleton. An initial factor
that promotes microvesicle formation is an increase in intracellular Ca2+, which is
driven by oxidative stress [56]. Increased Ca2+ inhibits inward aminophospholipid

14

translocase (flippase) and activates an outward translocase (floppase). This
aberrant

phospholipid

translocation

leads

to

an

externalization

of

phosphatidylserine (PS), a general characteristic of MV [57]. However, some
MVs do not have PS on the outer membrane leaflet [58]. Ca2+ overload also
activates caspases that lyse the cytoskeleton making it dissociate from the
plasma membrane at the budding site. MV pinch-off involves a cascade of
signaling that is triggered by the GTP-binding protein ADP-ribosylation factor 6
(ARF6). ARF6 activates phospholipase D leading to phosphatidic acid
generation, which recruits extracellular signal-regulated kinase (ERK) to the
plasma membrane. ERK subsequently phosphorylates myosin light-chain kinase
(MLCK), which further phosphorylates the myosin light chain (MLC). This
signaling cascade results in actomyosin-based contraction at the neck of the bud
leading to MV release [59].
Apoptotic Bodies Biogenesis
Unlike exosomes and MV formation, apoptotic bodies are generated by
dead cells. However, a common pathway observed in both apoptotic body
formation and MV formation is MLC phosphorylation, which is responsible for
membrane protrusion. Instead of an ARF-6 mediated process, membrane
blebbing of apoptotic cells is initiated by caspase-3 activation, which cleaves and
activates Rho-associated coiled-coil protein kinase 1 (ROCK-1), an enzyme that
phosphorylates MLC [60]. Because caspase activation causes DNA cleavage
and cytochrome c release from mitochondria, the remnants of this process, such
as nuclear DNA and mitochondrial fragments, can be found in apoptotic bodies.
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EVs as a Biomarker for Oxidative Stress-Related Diseases
DOX generates extensive quantities of oxidized and ubiquitinated proteins
while it disrupts multiple pathways of protein quality control as discussed above.
Because EV biogenesis and protein quality control pathways are interconnected,
EVs serve as an alternative pathway to remove toxic proteins from cells during
DOX-induced oxidative stress. Indeed, DOX can promote EV release in several
ways. DOX activation of p53 can increase MVB production via TSAP6 activation
[48,61]. In addition, DOX disrupts Ca2+ homeostasis in cardiomyocytes by
interfering with the electron transport chain leading to the potential collapse of the
mitochondrial membrane [62]. Inability to maintain mitochondrial membrane
potential inhibits Ca2+ influx into mitochondria, which results in an elevation of
cytosolic Ca2+, a key event that induces MV release. Lipid peroxidation by DOX
may affect membrane curvature and promote EV formation as evidenced by
photooxidation of artificial lipid membrane inducing alteration of its physical
property, in which the hydroperoxyl group increases the area of lipid membrane,
thus creating membrane budding [63]. The effect of DOX on protein quality
control pathways as well as EV biogenesis is summarized in Figure 1.1.
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Figure 1.1

DOX inhibits intracellular protein quality control

pathways while promoting extracellular vesicle release
DOX redox cycling at complex I leads to excessive ROS and RNS
generation in mitochondria, which leads to oxidation of a variety of
biomolecules (1). 4HNE is a reactive lipid peroxidation product that
can adduct to proteins and inactivate protein function (2). Oxidized
proteins as well as 4HNE-adducted proteins are subject to
degradation by protein quality control pathway including protein
unfolding, ubiquitin-proteasome pathway, and autophagy. Severe
protein oxidation due to DOX insults generates bulky misfolded
proteins, which overwhelm proteasome degradation, thus forming
protein aggregates (3). Autophagy is a major pathway to remove
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and recycle protein aggregates, as well as damaged organelles
such as mitochondria. DOX inhibits VATPase, a proton pump that
maintains lysosomal pH, as well as LAMP2A, a membrane
transporter of oxidized protein into lysosomal lumen for degradation
(4). Lysosomal dysfunction leads to an accumulation of oxidized
proteins, which can be alternatively sorted into MVB by ESCRT
complexes (5), as well as HSC70 (6). DOX-induced DNA damage
activates p53, which upregulates TSAP6, an endosomal membrane
protein responsible for MVB formation (7). Exosomes are
generated by fusion of MVB with the plasma membrane, and
release of the intraluminal vesicles into extracellular space (8).
DOX blocks mitophagy via p53-mediated PINK1 sequestration into
cytosol,

thus

preventing

autophagosome

formation

(9).

Dysfunctional mitochondria that cannot be cleared by autophagy
accumulate (10). Meanwhile, mitochondrial dysfunction induces
Ca2+ retention in cytoplasm (11), which in turn inhibits flippase and
activates floppase (12). PS externalization occurs due to floppase
activity (13). Increases in cytosolic Ca2+ also activate caspases,
which cleaves cytoskeleton and dissociates the membrane from
underlying structure, forming MVs (14). Adapted from Yarana et al.
Antioxidants (Basel). 2017 Sep 28;6(4)

Since the mechanisms by which DOX promotes EV release are based
primarily on oxidative stress, it follows that this concept can be applied to other
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chemotherapeutic agents that generate ROS/RNS as well. In fact, Hall and
colleagues found a significant increase in endothelial-derived MVs in the blood of
multiple myeloma patients treated with cyclophosphamide, thalidomide /
lenalidomide and dexamethasone when compared to baseline [64]. In addition,
cancer cells exploit EVs to remove intracellular chemotherapeutic drug and
promote

chemoresistant

phenotype.

Recently,

Muralidharan-Chari

and

colleagues reported that human pancreatic cancer cells release MVs to expel
gemcitabine—a chemotherapeutic that inhibits DNA synthesis. The ability of cells
to release MV for gemcitabine clearance correlated with the degree of drug
resistance, and inhibition of MV release sensitized the cells to gemcitabine [65].
For many reasons, EVs are more attractive for biomarker discovery than
conventional serum biomarkers. In addition to their stability and ability to carry a
variety of biomolecules, as discussed above, EVs are abundant in a variety of
body fluids, including blood, urine, saliva, milk, lymph, ascites, and amniotic
fluids. EVs that are released from viable tissues in the form of exosomes and
MVs serve as useful tools of early markers of tissue injury that are detectable
prior to cell death. Since EVs are highly associated with tissue redox status, a
study of oxidatively modified molecules will be beneficial for biomarker discovery
of oxidative stress-mediated diseases, especially chemotherapy-induced tissue
injury, where early cardioprotective intervention is a goal. Figure 1.2 shows
potential EV cargo that could be used as a biomarker for oxidative stress and
potential methods to identify those markers.
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Figure 1.2

Candidate molecules in EVs for oxidative stress

biomarkers
Adapted from Yarana et al. Antioxidants (Basel). 2017 Sep 28;6(4)

Cellular oxidative stress leads to the production of oxidatively modified
molecules such as oxidized lipids, oxidized proteins and mitochondrial DNA
(mtDNA) fragments, which are sorted to EVs for removal. Those oxidized
molecules as well as apoptotic nuclear DNA (nDNA) and tissue specific proteins,
mRNA and miRNA, can identify the origin as well as the oxidative status of the
releasing cells. Several methods, such as lipidomics, redox proteomics, RNA
microarray, PCR, and gene sequencing, can be applied to discover the potential
molecule to be used as a certain disease biomarker.
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Functions of EVs under Oxidative Stress Response
EVs play a key role in mediating cell-cell communication. They shuttle
bioactive lipids, mRNA, miRNA, as well as signaling proteins that drive biological
changes in recipient cells. EVs have advantages over other types of intercellular
communication because the signaling molecules inside them are protected from
enzymatic degradation. Thus, the messages can be delivered to sites away from
the releasing spot. The messages can also be delivered with high specificity to
recipient

cells

via

receptor-mediated

endocytosis

[66].

Intercellular

communication via EVs is critical to the progression of many oxidative stressrelated diseases, among them: cancer-microenvironment crosstalk—a key event
in cancer progression and metastasis [67]; spreading toxic protein aggregates in
neurodegenerative diseases [68]; and carrying damage and pathogen-associated
molecular patterns (DAMPs and PAMPs), autoantigens, and proinflammatory
cytokines to activate immune cells in inflammatory diseases [69]. In this review,
we discuss the role of EVs in the context of oxidative stress.
Table 1 summarizes the effect on recipient cells of EVs released under
different oxidative stress conditions. Briefly, oxidative stress conditions determine
the contents of EVs. Those contents can induce an oxidative stress response in
recipient cells either by helping to protect the releasing cells against further injury
or by exacerbating the injury. Although EVs serve as a compensatory
mechanism that deal with proteotoxicity, the consequences of proteotoxic cargo
transference to neighboring cells can be detrimental. Malik et al. have shown that
ROS induction in adult rat cardiomyocytes treated with ethanol or brief
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hypoxia/reoxygenation conditions leads to HSP60-containing exosome release
as HSP60 causes cardiomyocyte apoptosis [70]. However, spreading HSP60 by
exosomes to neighboring cells could activate Toll-like receptor 4 (TLR4)mediated apoptosis in the recipient cells [71]. In contrast, Eldh et al. reported that
mRNA profiles in exosomes change when mast cells are treated with H2O2 and
the exosomal mRNA helps mast cells tolerate higher doses of H2O2 [72]. Retinal
pigment epithelial cells treated with ethanol release exosomes that contain
vascular endothelial growth factor receptor as well as the mRNA of the protein,
and these exosomes promotes angiogenesis [73].
Table 1.1 Role of oxidative stress-related EVs on cell viability and tissue
inflammation
Cell / tissue
type of
origin

EV type

Cardiomyocyt Exosomes
es

Oxidative
stress
condition

Oxidative
stressrelated
cargo
HSP60

Effect

Referen
ce

TLR4mediated
apoptosis

Heiserm
an et al.
[68]

H2O2
tolerance
Angiogene
sis

Eldh
et al. [69]
AtienzarAroca
et al. [70]

Mast cells

Exosomes

Ethanol,
hypoxia /
reoxygenati
on
H2O2

Retinal
pigment
epithelial
cells
HEK293 cells

Exosomes

Ethanol

VEGF
protein and
mRNA

Exosomes
+
Microvesicl
es

Ca2+
ionophore
(Lipoxygena
se
stimulator)
High fat diet
treated mice
(NASH
model)

Oxidized
phospholipi
ds

TLR4mediated
NFκB
activation

MancekKeber
et al. [71]

Oxidized
mtDNA

TLR9induced
TNFɑ, IL-6
production

GarciaMartinez
et al. [72[

Liver

Microvesicl
es
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mRNA

Cai et al.
TLR9[73]
mediated
neutrophilic
inflammatio
n
Liver
Exosomes Alcoholic
miR-122
Sensitize
Momenhepatitis
monocytes Heravi
to LPS
et al. [74]
Liver
Microvesicl Saturated
TRAIL
DRSHirsova
es
fatty aciddependent et al. [75]
induced
macrophag
lipotoxicity
e activation
Macrophage Exosomes Myocardial
miR-155
Fibroblast
Wang
infarction
inflammatio et al. [76]
n
Cardiosphere EVs
Myocardial
Y RNA
IL-10
Cambier
-derived cells
infarction
fragment
expression et al. [77]
and
secretion
Adapted from Yarana et al. Antioxidants (Basel). 2017 Sep 28;6(4)
Liver

Microvesicl
es

Chronic plus mtDNA
binge
alcohol
drinking

EVs are well-known to function as an immunomodulator. EVs can present
cellular peptide antigen on their surface with major histocompatibility complex
(MHC) class I and class II molecules. The peptide antigen can activate T-cells
directly or indirectly by transfer to antigen-presenting cells. Accumulating
evidence indicates that EVs released under an oxidative stress condition can
stimulate immune cells. EVs from HEK293 cells treated with a Ca2+ ionophore
(A23187) or synthetic EVs treated with 15-lipoxygenase and Fenton reaction
contain lipid peroxidation products on their surface. These stress EVs activate
TLR4-mediated NFκB signaling and pro-inflammatory cytokine release from
macrophages [74]. Plasma from mice fed with a high fat diet contains oxidized
mtDNA-carrying MVs, which can induce TNFα and IL-6 production through TLR9
activation [75]. Oxidative stress in an alcoholic hepatitis model contains mtDNA
in hepatocyte-derived MVs, which can also activate TLR9 and promote

23

neutrophilic inflammation [76]. Another alcoholic hepatitis model presented
hepatocyte release exosomes with miR-122, a liver-specific miRNA. The miR122 in exosomes is biologically active in that it can inhibit heme oxygenase-1
making the monocyte more sensitive to LPS-induced TNFα and IL-1β production
[77]. Mouse and human hepatocytes treated with palmitate to induce lipotoxicity
release MVs that express TNF-related apoptosis-inducing ligand (TRAIL) on their
surface, which are recognized by death receptor 5 on macrophage resulting in IL6 release [78]. Immune cells can receive EVs-induced cytokine production signal
from non-immune cells. Wang et al. recently reported that myocardial infarction
induces macrophages to release exosomes-containing miR-155, which can
transfer to cardiac fibroblasts. This event leads to a downregulation of the
suppressor of cytokine signaling 1 (SOCS1)—a negative regulator of cytokine
signaling—thus promoting cardiac inflammation [76]. However, a recent study
from Cambier et al. found that the most abundant RNA in EVs released during
myocardial infarction from cardiosphere-derived cells are Y RNA fragment, a
small non-coding RNA. Delivery of Y RNA to macrophages upregulates IL-10
and protects cardiac tissue from ischemia/reperfusion injury [79].
Superoxide Dismutase and EV-Mediated Oxidative Stress Response
Superoxide dismutase (SOD) is a compartmentalized ROS detoxifying
enzyme that catalyzes the dismutation of O2•- to H2O2 and O2 [80,81]. Three
isoforms of SOD have been characterized in mammals. SOD1 (CuZnSOD) is a
homodimer that contains Cu and Zn at the catalytic cite. CuZnSOD is located
ubiquitously in cytoplasm, the mitochondrial intermembrane space, nucleus, and
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lysosome. SOD2 (MnSOD) is a Mn-containing homotetramer enzyme with a
mitochondrial localization sequence that makes it reside in the mitochondrial
matrix. SOD3 (ECSOD) is a Cu and Zn-containing homotetramer enzyme
localized on the cell surface by interaction of its C-terminal region with heparin
and other extracellular matrix proteins [82,83]. ECSOD can be detected in body
fluids such as plasma, lymph, ascites, synovial fluid, and cerebrospinal fluids
[84,85]. SOD plays a role in cell signaling under physiological as well as
pathological conditions. Recent studies have begun to reveal the interplay
between SOD and the EVs pathway. A discussion of the relationship between
SOD and EVs in the context of EVs-associated oxidative stress response follows.
SOD1
The SOD1 gene is located on chromosome 21 (21q22.1 region). The
SOD1 activity of a person with Down syndrome (trisomy 21) is 50% higher than
in the normal population. Although the mechanism of how SOD1 promotes the
Down syndrome phenotype is unknown, one possible explanation is an increase
in ratio of SOD1 activity over glutathione peroxidase 1 activity, which leads to
overproduction of H2O2—a key senescence mediator [86]. The well- established
link between SOD1 and human disease is typified by the development of
amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized
by the progressive loss of motor neurons in the corticospinal tract involving brain,
brainstem, and spinal cord. SOD1 mutations account for 1-4% of sporadic ALS
patients and 20% of familial ALS patients [87]. The SOD1 mutation interferes
with protein stability and folding, which leads to protein aggregation [88]. The
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aggregated SOD1 can be transferred to other neurons by contiguous
propagation to the neighboring neurons or by network propagation of synaptic
transmission [89]. Grad and colleagues found that aggregated SOD1 can be
released extracellularly with or without exosome association. The free SOD1 or
the exosome-associated SOD1 can be taken up by recipient cells. However,
many questions remain to be clarified in exosome-mediated SOD1 transfer. For
instance, how is aggregated SOD1 sorted into MVB, and is the SOD1 in the
exosomes degraded in the recipient cells by the lysosomal pathway or does it
cause proteotoxicity in the recipient cells?
SOD2
SOD2 is located exclusively within mitochondria. Its major role is to protect
mitochondria from the damaging effects of O2 [33]). Mice with a complete SOD2
knockout mice die in early post-natal life due to dilated cardiomyopathy [90]. Lifelong heterozygous deletion of SOD2 in mice reduces 50% of SOD2 activity and
leads to oxidative damage in all tissues, as evidenced by an elevation of 8-OHdG
in nuclear and mtDNA. Although aging is not affected by partial SOD2 deletion,
the mice have a two-fold higher incidence of developing tumors and 80% have
multiple tumors, including lymphoma, hemangioma, adenocarcinoma, and
pituitary adenoma [91].
Excessive ROS generation from mitochondria is a major mechanism of
DOX-induced

cardiotoxicity.

Our

lab

previously

discovered

that

SOD2

overexpression protects heart tissue from DOX-induced mitochondrial injury [92].
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In those animals, mitochondrial complex I is spared from O2•- insult [93].
Mitochondrial iron is a critical mediator of cardiotoxicity from DOX. Dexrazoxane,
an iron only chelator that is FDA-approved for use as a cardioprotective agent
against DOX toxicity, is more effective than other iron chelators since it can
reduce mitochondrial iron [94]. SOD2 affects mitochondrial iron similarly to the
effect of dexrazoxane. In mice, loss of SOD2 from erythroid progenitor cells
results in accumulation of mitochondrial iron leading to protein oxidation and
membrane deformity—a phenotype similar to ringed sideroblasts in hemolytic
anemia [95].
As discussed above, oxidative stress and impaired protein quality control
drive EV release, which in turn can promote further tissue damage and tissue
inflammation. Although the direct effect of SOD2 on EVs oxidative stress
response has not yet been investigated, we speculate that SOD2, which limits
ROS production, can reduce oxidative stress-related tissue injury during the first
wave of chemotherapy insult, as well as prevent the second wave of injury
mediated by damaging cell-derived EVs.
SOD3
SOD3 is a secretory CuZnSOD. The human SOD3 gene is localized on
the 4p-q21 region of chromosome 4 [96]. It shares 60% homology with the SOD1
gene but very low homology with the SOD2 gene. Human SOD3 mRNA is highly
enriched in certain tissues, including heart, placenta, pancreas, and lung, and
less enriched in kidney, skeletal muscle, liver and brain [97]. As it is located on
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cell surface and in the extracellular matrix, SOD3 plays a major protective role
against oxidative damage in the extracellular environment. NO in the
extracellular environment is crucial for maintaining cardiovascular homeostasis.
NO regulates vascular tone; inhibits platelet aggregation and leukocyte
adhesion; and prevents vascular inflammation. O2•- generated by Xanthine
oxidase, NADPH oxidase, and uncoupled endothelial nitric oxide synthase
interacts with NO forming ONOO-, which in turn oxidizes various biomolecules
leading to vascular dysfunction. SOD3 promotes bioavailability of NO by
removing the inhibitory O2•- molecule thus helping to maintain vascular function
[83].
A recent study by Iversen and colleagues revealed that SOD3 can also
reside in the intravesicular compartment of neutrophil in a resting state and be
released as a cargo of EVs when neutrophil is stimulated by formyl-methionylleucyl-phenylalanine or phorbal 12-myristate 13-acetate. The function of SOD3 in
EVs is preserved as EVs containing SOD3 can reduce O2•- in extracellular space
[98]. Indeed, neutrophils lack SOD3 mRNA. Thus, SOD3 in vesicles might
originate from other cells, transfer to neutrophil plasma membrane, and
subsequently are stored in endosomes ready for secretion when needed.
However, the original source of transferred SOD3 and the mechanism of how
SOD3 is taken up by neutrophils into secretory vesicles have not been
investigated. Understanding SOD3 transfer and storage by the EVs mechanism
may help develop a new therapeutic intervention for use of EVs as a vehicle to
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transfer SOD3 to the tissues that require this antioxidant enzyme but have limited
capacity to generate their own SOD3.
DOX-Induced Cardiomyopathy and Inflammation
The innate immune system plays a key role in regulating inflammation
during the progression of heart failure [99]. Proinflammatory cytokines, especially
TNFα, correlate very well with clinical symptoms of the patients [100]. Cardiac
inflammation also occurs in DOX-induced cardiomyopathy. Inflammatory cell
infiltration into heart tissue and the increase in plasma level of TNFα are
associated with left ventricular dysfunction induced by DOX [101]. However how
myocardial injury is sensed by the innate immune system to initiate inflammation
is not fully understood.
EVs and Immune Cells
EVs are known to regulate innate and adaptive immune influences to
execute both pro- and anti-inflammatory responses [102,103]. Most of studies
focused on the role of EVs on immune cells in response to pathological stress
such as injury, infection, cancer, and inflammatory diseases. On one hand, EVs
can activate innate immune cells by transferring a wide variety of proinflammatory cytokines including: IL-1 beta; inflammasome component caspase1 [104]; enzymes that generate ROS such as NADPH oxidase [105,106];
bioactive

lipids

such

as

eicosanoids

and

their

synthesizing

enzymes

cyclooxygenase and lipoxygenase [107]; miRNAs; pro-inflammatory mediators
such as platelet-activating factor [108] and TNF receptor [108]. EV-bearing
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antigen on major histocompatibility complexed class I (MHC-I) and class II (MHCII), can activate CD8+ and CD4+ T lymphocytes, respectively. The ability of EVs
to activate an immune response has been utilized for vaccine development
against cancer [109] and microbial infections [110]. However, for inflammatory
disease treatment, the pro-inflammatory EV effects need to be inhibited. Despite
much evidence demonstrating EV pro-inflammatory effects, EVs from certain cell
types are immunosuppressive. For instance, EVs from stem cells have
immunosuppressive properties and promote tissue repair and regeneration
mediated by anti-inflammatory transcription factors, mRNA, cytokines, enzyme,
and growth factor [111]. EVs from tumor cells have an ability to escape immunemediated cytotoxicity by expressing membrane-associated proteins such as
FasL, which can induce T lymphocyte cell death through activation of TNF
receptor I and Fas receptor [112], TGF beta and heat shock protein 72. These
factors activate regulatory T cells and Natural Killer Group 2D ligand, which
impair natural killer cell and CD8+ T cell function by a decoy effect, as well as
mRNA, miRNA and proteins that inhibit myeloid cell differentiation [113].
Macrophage Polarization in Tissue Injury and Tissue Repair
Macrophages are mononuclear phagocytic cells that play a critical role in
the innate immune response. Macrophages not only serve as a primary defense
mechanism to remove pathogens, toxicants and tissue debris, but also govern
inflammatory resolution and wound healing. To accomplish those functions,
macrophages must reprogram themselves to obtain different phenotypes called
macrophage polarizations. Macrophage polarizations are generally categorized
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into 2 extreme phenotypes, M1 and M2. M1 is a pro-inflammatory phenotype
characterized by a high expression of pro-inflammatory cytokines such as TNF
alpha, IL-6, and IL-1beta. M1 expresses high levels of inducible nitric oxide
synthase that generates nitric oxide to promote inflammation. For cellular
metabolism, M1 relies more on glycolysis than oxidative phosphorylation. In
contrast, M2 is an anti-inflammatory phenotype that suppresses inflammation
and promotes tissue repair. M2 is characterized by a high expression of antiinflammatory cytokines such as IL-10 and TGF beta. M2 expresses high antioxidant enzymes and relies more on mitochondrial OXPHOS. The balance of M1
and M2 function is critical to maintain tissue homeostasis. Excessive or
uncontrolled M1 macrophages lead to unresolved tissue injury and chronic
inflammation whereas excessive M2 activation leads to tissue fibrosis [114].
Redox Signaling in Macrophage Polarization
The process of M1 and M2 polarization involves redox regulation of
transcription factors, which upregulate or downregulate pro- and antiinflammatory cytokines, as well as anti-oxidant enzymes that counteract ROS
and RNS generation during the inflammatory process. The redox regulation can
occur at the level of their regulatory protein binding step in the cytoplasm or at
the DNA binding step in the nucleus.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a
transcription factor involved in many cellular processes including cell growth,
differentiation and inflammation. NFκB upregulates pro-inflammatory cytokines,
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chemokines, and adhesion molecules. In nonstimulated macrophages, NFκB is
sequestered in the cytosol by interacting with its inhibitory partner IκB, which
masks the NFκB nuclear localization sequence and prevents NFκB nuclear
translocation. Oxidative stress can activate NFκB by activating protein tyrosine
kinase, which subsequently phosphorylates IκB leading to IκB degradation by
proteasomes releasing NFκB from the inhibitory binding [115]. However, once
NFκB is translocated into the nuclease, oxidative stress inhibits its DNA binding
activity via nitrosylation of its cysteine residue, which is prevented by thioredoxin
[116].
Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) is a key transcription
factor responsible for a cytoprotective mechanism against oxidative stress by
enhancing anti-oxidant enzyme gene expression such as heme oxygenase-1
(HO-1), glutathione S-transferase, glutathione peroxidase, NAD(P)H quinone
oxidoreductase 1, and peroxiredoxin 1 [117]. Under normal conditions, Nrf-2
activity is inhibited by interacting with a ubiquitin ligase—Kelch-like ECHassociated protein (KEAP-1) leading to constitutive degradation of Nrf-2 by
proteasomes. However, a minimal amount of Nrf-2 can escape KEAP-1 binding
and localize to the nucleus to regulate basal anti-oxidant capacity. Under
oxidative stress conditions, the cysteine residues of KEAP-1 are oxidized and a
conformational changed KEAP-1 releases Nrf-2 from the inhibitory complex
[118]. Upon binding to an antioxidant responsive element (ARE) in the nucleus,
Nrf-2 heterodimerizes with a small Maf protein to transactivate the generation of
anti-oxidant enzymes. Several lines of evidence have shown that the anti-oxidant
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effect of Nrf-2 plays a key role in anti-inflammatory response [119-121]. However,
more recent evidence has revealed an anti-inflammatory effect of Nrf-2
independent of the anti-oxidant effect. Nrf-2 can directly interfere with proinflammatory cytokine gene expression by blocking the recruitment of RNA
polymerase II to IL-6 and IL-1 beta gene transcription start sites [122].
NFκB and Nrf-2 interdependently regulate each other by a Yin Yang-like
signaling. Inhibition of Nrf-2 increases NFκB activity and vice versa. Other than
Nrf-2, KEAP-1 can also interact with IKK and block IKK phosphorylation activity,
as well as induce IKK degradation, thus increasing the level of IκB and inhibit the
NFκB- IκB pathway [123]. HO-1, which is an Nrf-2 target, can directly inhibit
NFκB without its anti-oxidant property [124]. Lastly, Nrf-2 and NFκB compete to
bind the co-activator CREB binding protein [125].
Thioredoxin (TRX) is a small redox sensitive protein that contains 2 redoxactive cysteine residues in its active site—Cys-32 and Cys—35. TRX maintains
the reducing environment of the cells by the thiol-disulfide exchange reaction and
denitrosylation reaction. Moreover, TRX is also involved in an inflammation
signaling pathway by interacting with proteins that control immune activation
(Figure 1.3). Two isoforms of TRX have been identified. TRX1 primarily exists in
cytoplasm but it can be found in the nucleus or secreted out of the cell, while
TRX2 is located in mitochondria. Although TRX has an overlapping function with
glutathione (GSH) in controlling redox homeostasis, proteomic analysis revealed
distinct target proteins from GSH, suggesting selective functions of TRX
[126,127]. TRX has been shown to have an anti-inflammatory effect by
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enhancing M2 polarization in the presence of IL-4, as well as decrease the
inflammatory response induced by LPS [128].TRX1 can regulate NFKB in two
ways. Cytosolic TRX1 inhibits NFKB activation by preventing the dissociation of
IκB from NFκB [129].
However, if NFKB is translocated into the nucleus, TRX1 can promote the
NFκB DNA binding activity by preventing NFκB nitrosylation [130] and disulfide
bond formation at cysteine 62 of p50 subunit [116]. TRX1 can also regulate
NLRP3 inflammasome activation. TRX1 inhibits NLRP3 inflammasome by
interacting with thioredoxin-interacting protein (TXNIP) and prevent binding and
activation of TXNIP to NLRP3 inflammasome [131]. Furthermore, TRX1 can also
regulate Nrf-2 pathway. Direct interaction of TRX1 with Nrf-2 interacting protein,
Kelch-like ECH-associated protein (KEAP-1), maintains KEAP1 in a reduced
state thus preventing Nrf-2 nuclear translocation [132]. However, nuclear TRX1
has opposing function in promoting Nrf-2 transcription activity by keeping
cysteine 506 of Nrf2 in the reduced state [133].
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Figure 1.3

Regulation of Nrf-2 and NFκB by TRX1

Depending on its location, TRX1 regulates Nrf-2 and NFκB in the
opposite ways. Cytosolic TRX1 inhibits Nrf-2 and NFκB activation
by promoting the association of Nrf-2 with KEAP-1 and NFκB with
IκB thus blocking Nrf-2 and NFκB nuclear translocation. In contrast,
nuclear TRX1 promotes Nrf-2 binding to antioxidant response
element (ARE) and NFκB binding to its response element (NFκB RE) since TRX1 maintain Nrf2 and NFκB reduced state, which
leads to the upregulation of antioxidant genes and pro-inflammatory
genes.
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Research Objective
The aims of this study are to investigate whether EVs could be used as a
biomarker for DOX-induced cardiotoxicity and identify the effects of EVs on the
innate immune response during DOX treatment.
In chapter two, we report the characteristics of serum EVs released after
DOX treatment in mice, the tissue specific markers that indicate the major
sources of those EVs, the levels of oxidative stress marker—protein-bound
4HNE—in the EVs, as well as evaluate the potential of EVs to predict
cardiotoxicity from DOX.
In chapter three, we report the functions of EVs released from different
normal tissues exposed to DOX on macrophages. Our study investigated how
EVs from the tissues that have different levels of oxidative stress mediate
different effects on macrophage polarization, focusing on redox sensitive
molecule regulation.
The results from this study provide a novel, clinically applicable biomarker
that is superior to the conventional biomarker for DOX-induced cardiotoxicity.
Moreover, understanding the effects of EVs on macrophages will identify a new
target for treatment of DOX-induced tissue injury mediated by innate immune
activation.
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CHAPTER 2. CIRCULATING EXTRACELLULAR VESICLES IN A
DOXORUBICIN-INDUCED CARDIAC INJURY MOUSE MODEL CONTAIN
PROTEIN BIOMARKERS OF EARLY CARDIAC INJURY.
Overview
Significant advances in the efficacy of cancer therapy have been
accompanied by an escalation in side effects that result from therapy-induced
injury to normal tissues. The number of cancer survivors is now 15.5 million in
the United States alone, and is expected to rise by 31% to 20.3 million by 2026
(www.cancer.org). Cardiac injury is a major cause of death in cancer survivors,
but the current indicators of cardiac injury are detectable only after significant
damage has occurred. Thus, sensitive biomarkers are needed to permit early
intervention to prevent long-term cardiac injury after chemotherapy. In response
to stress conditions, tissues release extracellular vesicles into circulation. Using a
mouse model of DOX-induced cardiac injury, we quantified serum EVs, analyzed
proteomes, measured oxidized protein levels in serum EVs released after DOX
treatment, and investigated the alteration of EV content.
We found that treatment with DOX caused a significant increase in
circulating EVs (DOX_EVs) compared to saline-treated controls. DOX_EVs
exhibited a higher level of 4-hydroxynonenal adducted proteins, a lipid
peroxidation product linked to DOX-induced cardiotoxicity. Proteomic profiling of
DOX_EVs revealed the distinctive presence of brain/heart, muscle, and liver
isoforms of glycogen phosphorylase (GP), and their origins were verified to be
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heart, skeletal muscle, and liver, respectively. The presence of brain/heart GP
(PYGB) in DOX_EVs correlated with a reduction of PYGB in heart, but not brain
tissues. Manganese superoxide dismutase (MnSOD) overexpression as well as
pretreatment with cardioprotective agents and MnSOD mimetics resulted in a
reduction of EV-associated PYGB in mice treated with DOX. Kinetic studies
indicated that EVs containing PYGB are released prior to the rise of cardiac
troponin in the blood after DOX treatment, suggesting that PYGB is an early
indicator of cardiac injury.
Introduction
Chemotherapy can damage normal cells as well as cancer cells, and can
therefore result in late onset of side effects that compromise patient survivorship
and quality of life. According to the American Cancer Society’s Surveillance and
Health Services Research, as of 2014, around 6 million cancer survivors had
lived longer than ten years since their diagnosis (American Cancer Society, 2014
available from: http://www.cancer.org). Although they survived their cancer, these
patients may unfortunately suffer from complications of treatment, ranging from
non-fatal conditions such as cognitive dysfunction, neuropathy, and infertility, to
life-threatening conditions such as cardiomyopathy, myelodysplastic syndrome,
and secondary malignancy [134]. Severe adverse effects of chemotherapy can
also have a substantial economic impact due to hospitalizations and
prescriptions, costs for which are estimated at around $12,907 and $1,908 per
person per year, respectively [135]. This estimation reaffirms the significance of
preventing cancer treatment-related adverse effects.
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With the exception of secondary malignancies, cardiovascular disease is
the leading cause of death among cancer survivors [136]. Anthracyclines,
especially DOX, are the most common chemotherapeutic agents that cause
cardiomyopathy. However, their effectiveness and broad efficacy against more
types of cancer than any other class of chemotherapy make anthracyclines a
frequently used drug class [137].
DOX-induced cardiomyopathy presents as a decline of left ventricular
function that can develop many years after treatment cessation [5]. Cardiac
troponin-I (cTnI) and troponin-T (cTnT) are validated serological biomarkers for
DOX-induced cardiotoxicity. Although these biomarkers are specific in predicting
adverse outcomes from high-dose radiation and chemotherapy, the evidence for
low and moderate doses, as well as in asymptomatic childhood cancer survivors,
remains unclear [138,139]. Moreover, they are released after cardiac cell death
occurs, which is not an early event in the development of chemotherapy-induced
cardiotoxicity. Thus, it is not optimal to start cardioprotective interventions based
on cTnI or cTnT levels.
DOX-induced cardiotoxicity and other normal tissue injury begin with the
generation of reactive oxygen species (ROS) and reactive nitrogen species
(RNS), predominantly in the mitochondria [13,92]. Excess ROS/RNS results in
oxidative damage to biomolecules such as lipids, DNA, and proteins. Oxidative
modification of lipids and proteins leads to mitochondrial dysfunction [14] and
consequently activates cell death pathways [15]. To maintain cellular
homeostasis, the cells can remove oxidized proteins in several ways, e.g.,
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through

ubiquitin/proteasome-mediated

degradation,

autophagy,

and

extracellular vesicles (EVs). However, recent evidence has shown that extensive
and sustained oxidative stress during chemotherapy impairs cellular ability to
degrade oxidized proteins via the ubiquitin/proteasome and autophagy pathways
[25,34,140]. Therefore, EVs could be a major mechanism for oxidized protein
elimination during chemotherapy-induced tissue injury. We hypothesized that
circulating EVs could indicate the level of oxidative stress in targeted tissue
during chemotherapy and that they could be used as a liquid biopsy for highly
sensitive biomarkers of tissue injury resulting from chemotherapy.
EVs are membrane-bound structures released from most cell types into
the extracellular compartment. EVs are categorized into three types, based on
size and the mechanisms of biogenesis. Exosomes (50-100 nm) originate from
inward budding of the endosomal membrane, forming multivesicular bodies, and
are released by fusion of the multivesicular body membrane with the plasma
membrane. Microvesicles (0.2-2.0 m) are derived from plasma membrane
blebbing. Apoptotic bodies (1-2 m) are membranous globules released during
apoptotic processes [141].
EVs are attractive for biomarker discovery for many reasons. First, EVs
are stable in the extracellular environment because of the lipid bilayer that
protects their cargo from enzymatic degradation [142]. Second, EVs are highly
abundant in plasma/serum, with an estimated concentration around 1010 EVs per
mL [143]. Third, EVs carry proteins, lipids, and nucleic acids that reflect their
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tissues of origin and the condition of the releasing cells [19,144]. However, little is
known about the oxidative status, content, or tissue origin for circulating EVs
generated by chemotherapy-induced tissue injury.
In the present study, we investigated the protein content of EVs to
determine the potential profile for early detection of cardiac injury after DOX
treatment. We found that EVs present after DOX treatment contained signatures
of cardiac tissue and high levels of protein-bound 4-hydroxynonenal (4HNE),
which can be alleviated by enhancing tissue antioxidant capacity. Moreover, the
EVs and their protein contents are more sensitive than conventional serological
biomarkers for detection of DOX-induced tissue injury.
Materials and Methods
Animals
Male C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor,
ME). All mice had free access to food and water and were maintained on an
automatically timed 12 hour:12 hour dark cycle. All mouse-related procedures
followed the American Veterinary Medical Association Guidelines for the Care
and Use of Laboratory Animals and were approved by the Institutional Animal
Care and Use Committee at the University of Kentucky.
Treatment
The normal (non-tumor-bearing) mice at the age of 10-12 weeks and 2528 gram body weight were injected intraperitoneally (IP) with a single 20 mg/kg
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dose of doxorubicin hydrochloride (DOX; Bedford Laboratories, Inc., Bedford,
OH) or saline (SAL). Mouse weights were monitored daily after DOX treatment
until the animals were euthanized. The mice were euthanized and blood was
collected at 1, 24, 48 and 72 h from inferior vena cava after treatment. Blood was
allowed to clot by incubation at room temperature for at least 30 min and
centrifuged at 1,300 g for 15 min to yield the sera.
For pretreatment experiments, dexrazoxane (DRZ; Zinecard®, and Upjohn
Company LLC, Division of Pfizer Inc, NY) was administered at 200 mg/kg IP 30
min before DOX treatment [145]. The manganese superoxide dismutase
(MnSOD)

mi

metic

Mn(III)

meso-tetrakis(N-(n-butoxyethyl)pyridinium-2-

yl)porphyrin, MnTnBuOE-2-PyP5+ (MnP), was kindly provided by Dr. Ines BatinicHaberle and colleagues (Duke University School of Medicine, Durham, NC,
USA). MnP was injected IP at 2 mg/kg 30 min prior to DOX treatment.
Serum EV Isolation
For proteomic analysis, mouse serum EVs were isolated by sucrose
gradient centrifugation as previously described [146] with modifications.
Discontinuous sucrose gradient (10-70%) was prepared by slowly layering
sequentially decreasing sucrose density solutions from 70%, 55%, 40%, 25%,
and 10% from the bottom to the top of 5 ml ultracentrifuge tube, respectively
(Figure 2.1).
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Figure 2.1

Sucrose gradient preparation

Serum was thawed on ice and centrifuged at 12,000 g for 12 min at room
temperature to yield platelet-free serum. One ml of platelet-free serum was
layered on top of a 10-70% sucrose gradient in SW55 tubes (Beckman Coulter
Inc., Brea, CA, USA) with subsequent centrifugation at 100,000 g overnight.
Another one ml of platelet-free serum was layered on another sucrose gradient
tube. The samples from two sucrose gradient tubes were pooled together.
Fractions three to five from each tube, which contained EV markers CD63 and
CD81 (Figure 2.2), were collected. Each fraction was diluted in phosphatebuffered saline (PBS) and EV pellets obtained by centrifugation at 100,000 g for
70 min. The pellets from each fraction were resuspended in PBS and pooled.
The pooled suspension was centrifuged at 100,000 g for 70 min to obtain a final
pellet.
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Figure 2.2

Sucrose gradient isolation process for proteomics

analysis.
(A) Diagram showing the process of EV isolation by sucrose
gradient method (B) Western blot of EV markers, CD63 and CD81
of sucrose gradient fraction 1 to 5 (from the top to the bottom) and
(C) EV verification of isolation process by electron microscopy
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Adapted from Yarana et al. Clin Cancer Res. 2018 Apr
1;24(7):1644-1653.

For all other procedures, ExoQuick precipitation solution (System
Biosciences, Mountain View, CA, USA) was used to isolate EVs. From 200-250
μL of mouse serum, cells and cellular debris were pelleted by centrifugation at
3,000 g for 15 min, and 50-63 μL ExoQuick solution was added to the
supernatants. The mixture was incubated at 4°C for 30 min, and the EV pellet
was obtained by centrifugation at 1,500 g for 30 min. The supernatant was
aspirated, and the residual ExoQuick solution was removed without disturbing
the pellets after centrifugation at 1,500 g for 5 min. EV pellets were resuspended
in sterile water or PBS and stored at -80 °C.
Transmission Electron Microscopy (TEM)
Fresh, unfrozen EV pellets were resuspended in 2% paraformaldehyde
and adsorbed onto Formvar-carbon coated grids by applying 5 μl of EV
suspension on to the grid and let it air dry for 20 min. Then, the grids were
washed by applying a 50-μl drop of PBS on them. Then filter paper was used to
remove PBS from the grid. The washing step was repeated three times. After
that, the samples were fixed with 50-μl drops of 1% glutaraldehyde for 5 min
followed by the washing step. Then, the grids were stained with 50-μl drops of
uranyl oxalate, pH 7, for 5 min. Next, the grids were then embedded in 50-μl
drops of a mixture of 4% uranyl acetate and 2% methylcellulose for 10 min on
ice. Finally, the excessive fluid on the grids was gently removed by slowly
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dragging the fluid on Whatman no. 1 filter paper so that only thin films were left
on the grids. The grids were air dried for 5 to 10 min prior to TEM. EVs were
visualized by TEM at 80 kV [147].
EV Quantification and Size Measurement
EVs

in

PBS

suspension

were

quantified

by

measuring

protein

concentration using the bicinchoninic acid method. For size measurement, the
EV suspension was diluted with PBS to a concentration of 100 µg/mL. The size
distribution of EVs was evaluated by dynamic light scattering using the Zetasizer
Nano ZS (Malvern, Worcestershire, UK). The laser was operated at a 173° angle
with temperature set at 4°C.
Protein-Bound 4HNE Measurement
EVs from DOX- or SAL-treated mice (DOX_EVs and SAL_EVs,
respectively) were lysed with radioimmunoprecipitation assay (RIPA) buffer and
the lysates were mixed with an equal volume of Laemmli buffer. Protein-bound
4HNE levels were assessed by slot blot as previously described [148]. The
protein bands were visualized and the intensities were quantified by Adobe
Photoshop (San Jose, CA) and Scion Image, respectively. Band intensities for
protein-bound 4HNE for DOX_EVs were normalized by those obtained from
SAL_EVs, and reported as a fold change after the treatment.
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Sample Preparation for Mass Spectrometry (MS)
EV samples from sucrose gradient centrifugation were lysed with RIPA
buffer and sonicated at room temperature for 30 sec 3 times. Equal protein
aliquots (10 µg) from SAL_EV and DOX_EV samples were used for proteomic
analysis. EV lysates were reduced with -mercaptoethanol and heated to 95°C
for 5 min. The samples were electrophoresed on an 8% SDS-PAGE gel at 60 V
for 15 min to allow protein migration into the top of the gel. Next, the gel was
placed into a clean container and 50ml of SYPRO Ruby gel stain (BIO-RAD) was
added. The gel with the stain was agitated on an orbital shaker overnight at room
temperature. The next day, the gel was rinsed in 7% acetic acid for 30 min to
remove background fluorescence. The stained protein bands were visualized
using UV transilluminator and were then excised and subjected to liquid
chromatography/tandem MS (LC-MS/MS) (Figure 2.2A).
LC-MS/MS
Proteomic analysis was performed by the University of Kentucky
Proteomics Core Facility. Protein samples, processed as indicated above, were
reduced with dithiothreitol, alkylated by iodoacetamide, and digested by a
standard protocol of in-gel trypsin digestion. Shotgun proteomic analysis was
used as described previously [149]. The tryptic peptides were subjected to nanoLC-MS/MS analysis using an LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific, Waltham, MA) coupled with an Eksigent Nanoflex cHiPLC™ system
(Eksigent, Dublin, CA) through a nano-electrospray ionization source.
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MS/MS Protein Identification
The LC-MS/MS data were submitted to a local Mascot server. Proteins
were identified by Proteome Discoverer (version 1.3, Thermo Fisher Scientific)
against a Mus musculus taxonomy subset of the Swissprot database. Proteomic
analysis was performed twice. A decoy database was built and searched. Filter
settings that determine false discovery rates were used to distribute the
confidence indicators for the peptide matches. Peptide matches that pass the
filter associated with the strict false discovery rates (with target setting of 0.01)
were assigned as high confidence. Peptides that were identified in both
experiments on either the DOX_EVs or the SAL_EVs were considered
unambiguous.
Western Blot Analysis
EVs or serum samples were lysed with RIPA buffer, mixed in Laemli buffer
with or without beta-mercaptoethanol, and separated by electrophoresis through
an 8% SDS-PAGE gel. Proteins were transferred to nitrocellulose membranes.
The blots were blocked with Odyssey® Blocking Buffer (LI-COR, Lincoln, NE,
USA) and incubated overnight at 4°C with the primary antibodies. Primary
antibodies used in this study were: anti-CD63 (1:200; Santa Cruz, Santa Cruz,
CA, USA); anti-Alix (1:200; Santa Cruz); anti-HSC70 (1:200, Santa Cruz); antibrain/heart glycogen phosphorylase (PYGB) (1:500, Abgent, San Diego, CA,
USA); anti-muscle glycogen phosphorylase (PYGM) (1:500, Bioss, Woburn, MA,
USA); anti-liver glycogen phosphorylase (PYGL) (1:500, GeneTex, Irvine, CA);
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anti-vinculin (1:200, Santa Cruz), and anti-tubulin (1:200, Santa Cruz). After
several washes, the blots were incubated with IRDye® anti-mouse, rabbit, or goat
secondary antibodies (LI-COR) at a dilution of 1:5000 to 1:10,000 for 1 h at room
temperature. Washed membranes were scanned and the band intensities
measured by the Odyssey Imaging System.
EV Immunoprecipitation
SAL_EVs, DOX_EVs, and DOX-treated heart tissue (400 µg) were
immunoprecipitated with 4HNE-coated beads. 4HNE antibody was purchased
from Abcam (Cambridge, MA). SureBeadsTM protein A magnetic beads
purchased from Bio-rad (Hercules, CA). The beads at the volume of 100 μl (1
mg/ml) were magnetized and wash 3 times with PBS containing 0.1% Tween-20
and incubated with 5 μg of 4HNE antibody for 1 hour at room temperature. After
the washing step, the beads were incubated with SAL_EVs or DOX_EVs at 4°C
overnight. The next day, the beads were magnetized and the supernatants were
collected. Immunoprecipitated EVs were lysed with RIPA buffer. Supernatant
EVs were lysed with RIPA buffer and concentrated with 3 kDa centrifugal filters
(MilliporeSigma, Norwood, OH) to get a sample equal in volume to the
immunoprecipitated EVs. Then all of the sample lysates were mixed with
Laemmli buffer and boiled at 95°C for 5 min before running gel electrophoresis
(Figure 2.3).
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Figure 2.3

Diagram illustrating 4HNE immunoprecipitation of

serum EVs.
Serum EVs were immunoprecipitated using magnetic beads coated
with antibody against 4HNE, which recognizes 4HNE adducted
proteins on EV surface. After the pulldown process, the EVs would
be separated into two groups. EVs in the supernatant are the EVs
without 4HNE adduction on the surface (labelled in blue). EVs
captured by 4HNE antibody-coated beads are the EVs with 4HNE
adduction (labelled in red). EVs from both groups were lysed with
RIPA buffer. After lysis, the supernatant was concentrated with 3K
centrifugal filter to make it the same volume as the pulldown. Then,
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the samples were mixed with Laemmli buffer and boiled at 95 C for
5 min before going through western blotting process. Adapted from
Yarana et al. Clin Cancer Res. 2018 Apr 1;24(7):1644-1653.

Measurement of Serum Protein Biomarkers for Tissue Injuries
Cardiac injury was assessed by measuring serum cTnI levels from SALand DOX-treated mice. Creatine kinase isoenzyme MM (CKMM) and alanine
transferase (ALT) were used as biomarkers for skeletal muscle and liver injury,
respectively. Values were obtained using commercial ELISA kits as follows: cTnI
(Life Diagnostic, West Chester, PA), CKMM (LifeSpan Biosciences, Seattle, WA),
and ALT (MyBioSource, San Diego, CA).
Statistical Analysis
Differences between means of GP isoforms in tissues and in EVs, as well
as cTnI, ALT, and CKMM comparing between SAL- and DOX-treated mice were
analyzed by Student’s t-test. Differences between means for DOX-treated and
other parameters were analyzed by a two-way ANOVA followed by Tukey’s test.
P-values <0.05 were considered statistically significant.
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Results
DOX_EVs had aberrant morphology and larger size when compared to
SAL_EVs
To investigate if DOX treatment affected the characteristics of circulating
EVs, SAL_EVs and DOX_EVs were visualized by TEM. The morphology of EVs
observed under high-magnification TEM revealed that SAL_EVs were round,
membranous structures with a smooth surface. In contrast, the membrane of
DOX_EVs was irregular and the size of the vesicles was larger than that of
SAL_EVs (Figure 2.4A). The difference in EV size was confirmed by dynamic
light scattering analysis, which also showed that DOX_EVs have a broader size
distribution (13.9 ± 3.5 to 204.0 ± 46.4 nm) compared to SAL_EVs (4 ± 0.6 to 123
± 34.8 nm) (Figure 2.4B).
To verify that the pellets from the ExoQuick precipitation were composed
of EVs, equal amounts of pellets derived from SAL- or DOX-treated mouse
serum were subjected to immunoblotting to detect the proteins that were
enriched in the EVs. Proteins specific to EVs include CD63 (a tetraspanin protein
expressed on cellular membranes, including exosomes and microvesicles) and
Alix (an endosomal sorting complex required for transport). CD63 and Alix were
detected in pellets from SAL_EVs and DOX_EVs. However, calnexin, an
endoplasmic reticulum protein commonly detected in apoptotic bodies, could not
be identified in the EV samples (Figure 2.5). This result suggests that the pellets
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from the isolation process represented exosomes and microvesicles but not
apoptotic bodies.

Figure 2.4

Morphology and size of DOX_EVs were different

from SAL_EVs
(A) Representative electron micrograph of mouse serum EVs (high
magnification, X49,000). The numbers represent the diameter of
the vesicles. (B) Graphic representation of the distribution in EV
size. Presented data are the percent intensity of scattered light of
EVs from mouse serum. Blue line represents SAL_EVs’ size
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distribution. Red line represents DOX_EVs’ size distribution
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr
1;24(7):1644-1653.

Figure 2.5

Western blot of EV markers, CD63 and Alix in

serum EVs
Serum EVs from saline-treated and DOX-treated mice contained
markers for EVs but not apoptotic body marker Calnexin; the cell
lysate was used as a positive control. Adapted from Yarana et al.
Clin Cancer Res. 2018 Apr 1;24(7):1644-1653.

Increased levels of circulating EVs and protein-bound 4HNE after DOX
treatment
In order to assess the change in the amount of serum EVs over time, we
quantified serum EVs by measuring protein levels in the EV pellets isolated from
equal volumes of serum at 1, 24, and 72 h after treatment. While the amount of
serum EV protein after SAL treatment remained unchanged, the amount of EV
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protein significantly increased over time after DOX treatment, beginning at 24 h
(Figure 2.6A). The increase in serum EV quantity after DOX treatment was
confirmed by TEM (Figure 2.6B).

Figure 2.6

DOX-treated mouse serum contained more EVs

than SAL-treated mouse serum
(A) EV protein levels in 250 l serum from saline-treated (blue line)
and DOX-treated (red line) mice (mean ± SD, n = 5-6, where n =
number of 250 l-serum samples used for EV isolation, * p < 0.01
vs 1 h, # p < 0.01 vs Saline. (B) Representative electron
micrograph of mouse serum EVs (low magnification, X23,000) at 72
h post treatment. Adapted from Yarana et al. Clin Cancer Res.
2018 Apr 1;24(7):1644-1653.

4HNE is a major lipid peroxidation product that appears in cell membranes
during oxidative stress. 4HNE is highly reactive and can adduct to biomolecules,
resulting in functional changes in those molecules. Here we found that circulating
EVs contained higher protein-bound 4HNE levels after DOX treatment (Figure
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2.7). The protein-bound 4HNE levels peaked as early as 24 h post-DOX
treatment and remained higher than SAL-treated controls at 72 h.

Figure 2.7

DOX-treated mouse serum contained higher level

of protein-bound 4HNE than SAL-treated mouse serum
Fold change of protein-bound 4HNE in EVs from mice treated with
saline (SAL) or DOX for 1 h, 24 h and 72 h (mean ± SD, n = 6 * p <
0.05 vs Saline at the same time point. Adapted from Yarana et al.
Clin Cancer Res. 2018 Apr 1;24(7):1644-1653.

Serum EV proteomic profile altered after DOX treatment
To identify EV protein contents that might indicate the tissues of origin and
potential function of EVs during DOX-induced tissue injury, we performed
proteomic analysis of DOX_EVs and SAL-EVs after 72 h of treatment. Figure
2.8A shows the number of proteins identified in SAL_EVs and DOX_EVs. The
proteomic profiling identified 197 proteins expressed in both SAL_EVs and
DOX_EVs. Among the proteins enriched only in SAL_EVs, transferrin receptor 1
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(TfR1) and class I histocompatibility antigen (MHC-I) were identified with high
confidence, with ion scores above 50 (Figure 2.8B). In contrast, haptoglobin (Hp)
and glycogen phosphorylase (GP) isoforms from brain (PYGB), muscle (PYGM),
and liver (PYGL) were uniquely expressed in DOX_EVs (Figure 2.8C).

B. Proteins that are only expressed in SAL_EV
Protein
Protein Name
Score Coverage
Q62351
Transferrin receptor protein 1
884.79
36.04
P14430
H-2 class I histocompatibility
57.63
4.29
antigen, Q8 alpha chain
57.63
3.92
P06339
H-2 class I histocompatibility
antigen, D-37 alpha chain
P01897
H-2 class I histocompatibility
57.04
3.59
antigen, L-D alpha chain
C. Proteins that are only expressed in DOX_EV
Protein
Protein Name
Score Coverage
Q61646
Haptoglobin
231.11
31.70
Q9WUB3 Glycogen phosphorylase, muscle 166.80
25.06
form
Q8C194
Glycogen phosphorylase, brain 172.00
12.22
form
O88990
Alpha-actinin-3
108.98
3.67
Q9ET01
Glycogen phosphorylase, liver
80.71
4.59
form
P52480
Pyruvate kinase PKM
59.36
6.97
Figure 2.8

Proteomic profiling of circulating EVs

(A) Venn diagram showing the number of proteins found in EVs
from SAL (blue) and DOX-treated (red) mice. (B) List of proteins
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found exclusively in EVs from SAL-treated mice. (C) List of proteins
found exclusively in EVs from DOX-treated mice. Score = ion score
of the peptide; Coverage = % of protein sequence covered by
identified peptide. Adapted from Yarana et al. Clin Cancer Res.
2018 Apr 1;24(7):1644-1653.

EVs containing tissue-specific GP were released from DOX target tissues
GP is a tissue-specific protein with isoforms expressed in a tissue-specific
manner, as indicated by their names. PYGB is highly expressed in heart and
brain, PYGM is highly expressed in skeletal muscle, and PYGL is highly
expressed in the liver (Figure 2.9). Because heart/brain, liver and skeletal
muscle are organs known to be affected by DOX, the presence of these GP
isoforms in serum EVs might serve as a potential biomarker of DOX-induced
tissue injury.
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Figure 2.9

Western blots indicating PYGB, PYGM, and PYGL

are tissue-specific proteins
PYGB is highly expressed in heart and brain. PYGM is highly
expressed in skeletal muscle. PYGL is highly expressed in liver.
Vinculin and tubulin were used as appropriate positive controls.
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr
1;24(7):1644-1653.

Western blot analysis showed that all three GP isoforms as well as the EV
marker, HSC70, were enriched in DOX_EVs as compared to total serum (Figure
2.10A). All isoforms were scarcely detected in the serum, confirming that they
were highly enriched in the EV fraction rather than released as soluble proteins.
The existence of PYGB, PYGM, and PYGL inside the EVs was further confirmed
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by their resistance to proteinase K digestion due to the protection of the lipid
bilayer (Figure 2.11). These data clearly confirmed the proteomic data, i.e., that
PYGB, PYGM, and PYGL were only detected in DOX_EVs but not SAL_EVs.
The levels of PYGB, PYGM, and PYGL were also examined in heart and brain,
skeletal muscle, and liver tissues, respectively. Upon DOX treatment, PYGB was
significantly decreased in heart tissue, but not in brain tissue, suggesting that it
was released from damaged heart tissue of DOX-treated animals (Figure 2.10B
and 2.10C). This result is consistent with the notion that DOX did not cross the
blood brain barrier, and thus the brain is not a direct target tissue of DOX.
Similarly, PYGM levels decreased in skeletal muscle and PYGL decreased in the
liver after DOX treatment (Figure 2.10B and 2.10C). These results suggest that
EVs that contained PYGB, PYGM, and PYGL were released from the heart,
skeletal muscle, and liver, respectively.
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Figure 2.10 EV-containing glycogen phosphorylase isoforms
are associated with DOX-induced tissue injuries
(A) Western blot of PYGB, PYGM, PYGL obtained from EVs
isolated by sucrose gradient centrifugation and from whole serum
protein, HSC70 was used as an EV marker and loading control for
EVs. (B) Western blot of PYGB, PYGM and PYGL levels obtained
from heart, brain, skeletal muscle and liver lysates isolated from
Saline- and DOX-treated mice. Vinculin was used as a loading
control for heart and brain tissues; beta tubulin was used as a
loading control for skeletal muscle and liver. (C) Graphic
representation of western blot band intensities of PYGB, PYGM
and PYGL in the relevant highly enriched tissues and normalized
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by the appropriate loading control (mean ± SD, n = 6, n = number
of animals/group, * p < 0.05). Adapted from Yarana et al. Clin
Cancer Res. 2018 Apr 1;24(7):1644-1653.

Figure 2.11 Western blots confirming the existence of PYGB,
PYGM, and PYGL in SAL_EVs and DOX_EVs after treatment
with proteinase K
Cell lysate was used as a positive control for PYGB, PYGM and
PYGL detection. IgG and albumin were measured as a reference
for proteinase K efficiency to digest extravesicular proteins.
Adapted from Yarana et al. Clin Cancer Res. 2018 Apr
1;24(7):1644-1653.
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EVs with 4HNE adduction but not 4HNE-free EVs were released from DOX
target tissues
Because EVs can contain oxidative stress markers such as 4HNEadducted proteins and tissue-specific proteins such as GPs in the same
structure, we investigated further if EVs containing protein-bound 4HNE were
released from specific DOX target tissues. In this way, EVs might reveal their
tissue of origin and the etiology of cellular stress that induced their release. To
this end, we immunoprecipitated serum EVs with anti-4HNE antibody and
compared the tissue-specific GPs in those EVs to the protein profile in EVs that
did not have 4HNE bound. PYGB, PYGM, and PYGL were detected in 4HNE
pull-downs but not in the supernatant (Figure 2.12). Moreover, EV markers
flotillin-1 and HSC70 were more strongly detected in the pull-downs than in the
supernatant. This result suggested that the majority of circulating EVs are 4HNEadducted and that these EVs are released from DOX target tissues that have
high oxidative stress.
Next, we investigated if the level of EV-associated protein-bound 4HNE
can be changed by enhancing antioxidant capacity. First, we measured the level
of protein-bound 4HNE from serum EVs of MnSOD transgenic (MnSOD Tg) mice
that express approximately two-fold higher MnSOD level (9) compared to wildtype mice. In SAL-treated MnSOD Tg mice, the level of EV-associated proteinbound 4HNE did not differ from wild-type mice. However, after DOX treatment,
MnSOD Tg mice had significantly lower levels of protein-bound 4HNE than the
wild-type mice (Figure 2.13A).
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Figure 2.12 EVs with 4HNE adduction are released from direct
target tissues of DOX
Western blot to detect PYGB, PYGM, PYGL, as well as EV markers
flotillin-1 and HSC70, in 4HNE-immunoprecipitated SAL_EVs and
DOX_EVs and supernatant. Heart tissue lysate was used as a
positive control. Adapted from Yarana et al. Clin Cancer Res. 2018
Apr 1;24(7):1644-1653.
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Figure 2.13 The release of EVs with 4HNE adduction are
alleviated by antioxidant enhancement
(A) The level of EV-associated protein-bound 4HNE from wild-type
and MnSOD Tg mice after SAL or DOX treatment for 72 h. (B) The
level of EV-associated protein-bound 4HNE from mice pretreated
with vehicle, MnP (2 mg/kg) or DRZ (200 mg/kg) 30 min before SAL
or DOX treatment. (mean ± SD, n = 6-8, n = number of 250 lserum samples used for EV isolation, * p < 0.05 vs Saline, # p <
0.05 vs wild-type DOX) Adapted from Yarana et al. Clin Cancer
Res. 2018 Apr 1;24(7):1644-1653.

To determine if exogenously supplied antioxidants can exert a protective
effect similar to that observed in the transgenic mice, we used two antioxidantenhancing drugs, MnP and DRZ, as a tool to study the effect of exogenous
antioxidants on EV-associated protein-bound 4HNE levels. MnP is a MnSOD
mimetic, redox-active compound that works similar to endogenous MnSOD and
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has been shown to protect against DOX-induced cardiotoxicity [15]. DRZ is a
clinically approved drug for anthracycline-induced cardiotoxicity prevention. DRZ
acts as an antioxidant by removing iron from iron-DOX complexes [94]. We found
that MnP pretreatment but not DRZ pretreatment significantly reduced the level
of EV-associated protein-bound 4HNE when compared to DOX treatment alone
(Figure 2.13B).
DOX-induced cardiotoxicity is the most concerning side effect from cancer
treatment. Since the amount of EVs released is correlated with the degree of
tissue oxidative stress, we further measured the amount of EVs released from
heart tissue by using PYGB as a specific cardiac marker. To calculate the total
amount of EV-encapsulated PYGB (EV_PYGB) in 200 L of serum, the western
blot band intensities were nomalized by the total amount of EV protein in 200 L
of serum from each mouse. The result showed that EV released from heart
tissues as indicated by EV_PYGB in wild-type and MnSOD Tg mice did not
change after SAL treatment. However, EV_PYGB in DOX-treated MnSOD Tg
mice was significantly lower than DOX-treated wild-type mice (Figure 2.14A).
The decrease in serum EV_PYGB was associated with more retention of PYGB
in heart tissue of DOX-treated MnSOD Tg mice compared to DOX-treated wildtype mice (Figure 2.14B). Pretreatment with exogenous antioxidants that have
cardioprotective effects such as MnP and DRZ significantly decreased the level
of EV_PYGB in DOX-treated mice when compared to DOX treatment alone
(Figure 2.15A). However, MnP more effectively prevented EV release from heart
tissue than DRZ (Figure 2.15A). The level of serum EV_PYGB after antioxidant
66

treatment was also associated with the retention of PYGB in heart tissue (Figure
2.15B).

Figure 2.14 Overexpression of MnSOD prevents the release of
EV-containing PYGB and promotes the retention of PYGB in
heart tissues
(A) Western blot band intensities of PYGB in EVs from 200 µL of
serum comparing between wild type and MnSOD transgenic mice
treated with saline or DOX. (B) PYGB normalized to vinculin from
heart tissues of wild-type and MnSOD Tg mice treated with saline
or DOX. (mean ± SD, n = 6-8, n = number of 250 l-serum samples
used for EV isolation, * p < 0.05 vs Saline, # p < 0.05 vs wild-type
DOX) Adapted from Yarana et al. Clin Cancer Res. 2018 Apr
1;24(7):1644-1653.

67

Figure 2.15 Pretreatment with MnP or DRZ prevents the
release of EV-containing PYGB and promotes the retention of
PYGB in heart tissues
(A) Western blot band intensities of PYGB in EVs from 200 µL of
serum from mice pretreated with vehicle, MnP (2 mg/kg) or DRZ
(200 mg/kg) 30 min before SAL or DOX treatment (B) Western blot
band intensities of PYGB in heart tissues from mice pretreated with
vehicle, MnP or DRZ (mean ± SD, n = 6-8, n = number of 250 lserum samples used for EV isolation, * p < 0.05 vs Saline, # p <
0.05 vs control DOX). Adapted from Yarana et al. Clin Cancer Res.
2018 Apr 1;24(7):1644-1653.

EV-encapsulated GPs are sensitive indicators of DOX-induced tissue injury
Because EV release is a compensatory mechanism that the cell uses to
remove toxic molecules before cell death occurs, EVs could be a sensitive
biomarker for predicting tissue injury from chemotherapy. Here, we compared the
sensitivity of EV-encapsulated GPs to the conventional tissue injury markers
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such as cTnI for heart injury, ALT for liver injury, and CKMM for muscle injury.
The data from western blotting showed clearly that the levels of EV_PYGB,
EV_PYGM, and EV_PYGL were significantly increased in DOX-treated mice
(Figure 2.16A-2.16D). We did not use any EV protein markers for normalization
because the markers are uniquely expressed in specific subsets of EVs [150].
Since DOX_EVs and SAL_EVs were composed of different subsets of EVs as
indicated by the size, there was no appropriate protein to normalize the values.
Intriguingly, the elevation of EV-associated PYGB, PYGL, and PYGM after
DOX treatment was proportionally higher than cTnI, ALT, and CKMM,
respectively (Figure 2.16A-2.16G), suggesting that GPs are more sensitive than
the conventional biomarkers to detect DOX-induced tissue injuries. Moreover, by
measuring EV_PYGB by ELISA, we detected significant differences between
SAL- and DOX-treated mice as early as 24 h post-treatment, whereas
differences in cTnI were not detected until 72 h post-treatment (Figure 2.17A
and 2.17B). These data suggest that EV_PYGB is better than the conventional
serological markers at early detection of DOX-induced cardiac injury.
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Figure 2.16 EV-associated

glycogen

phosphorylases

are

sensitive DOX-induced tissue injury markers
(A) Western blots display PYGB, PYGM, and PYGL expression in
EVs from mice treated with saline or DOX for 72 h. (B-D) Western
blot band intensities for PYGB, PYGL, and PYGM levels (mean ±
SD, n = 6, n = number of 250 l-serum samples used for EV
isolation, * p < 0.05 vs SAL). (E-G) Serum levels of cTnI, ALT, and
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CKMM measured by ELISA obtained from the SAL- and DOXtreated mice in the same set of samples presented in A-D (mean ±
SD, n = 6, n = number of mice, * p < 0.05 vs SAL). Adapted from
Yarana et al. Clin Cancer Res. 2018 Apr 1;24(7):1644-1653.

Figure 2.17 EV_PYGB can predict DOX-induced cardiotoxicity
earlier than cTnI
Comparison of cTnI (mean ± SD, n = 6, n = number of mice, * p <
0.05 vs SAL at the same time point) (A) Comparison of EV_PYGB
at different time points after SAL and DOX treatment (mean ± SD, n
= 6, n = number of 250 l-serum samples used for EV isolation, * p
< 0.05 vs SAL at the same time point, # p < 0.05 vs DOX at 1 h, 24
h and 48 h) (B). Adapted from Yarana et al. Clin Cancer Res. 2018
Apr 1;24(7):1644-1653.

Discussion
Oxidative stress-mediated tissue injury is a major side effect of
chemotherapy that can lead to multiple organ dysfunction. However, biomarkers
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that are available to detect specific tissue injuries have not been linked to
oxidative stress and are released only after cell death occurs. In this study, we
exploited two properties of serum EVs that make them ideal early biomarkers for
chemotherapy-induced tissue injury: lipid peroxidation, and tissue-specific
proteins inside the EVs. Here, we demonstrated for the first time that EVs
released from normal tissues affected by DOX have aberrant membrane
morphology and higher protein-bound 4HNE levels. Proteomic analysis revealed
that PYGB, PYGM, and PYGL are specific indicators for the tissue of origin of
EVs released post-chemotherapy, which are brain/heart, skeletal muscle, and
liver, respectively. Importantly, serum EVs are indicators of the level of tissue
oxidative stress, as evidenced by the attenuation of 4HNE protein adduction, as
well as the decreased release of EVs from heart tissue with enhanced
antioxidant capacity. Thus, measurement of EV-associated protein-bound 4HNE
and the tissue-specific cargo proteins may overcome the limitations encountered
with the use of serum oxidative stress markers in terms of stability, extracellular
oxidation, and specificity for the target tissue oxidative status.
Lipid peroxidation products are one of the major effects of treatment with
DOX. With TEM, we observed that the DOX_EV membrane was irregular.
Changes associated with the DOX_EV membrane morphology might be a
consequence of lipid peroxidation, which can influence the surface area,
thickness, and permeability of the lipid membrane [63,151,152]. The larger size
of DOX_EVs compared to SAL_EVs may result from a property of the lipid
membrane, or the shift from exosome release to microvesicle release under
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oxidative stress. The evidence for lipid peroxidation on the EV surface was
strengthened by the observation of elevated protein-bound 4HNE after DOX
treatment. The level of protein-bound 4HNE in EVs increased within 24 h after
DOX treatment, which is consistent with our previous reports, in which 4HNE
adduction accumulated in cardiac tissues as early as 3 h, peaking at 6 h, with a
subsequent decline at 24 h [13,153]. The disappearance of protein-bound 4HNE
from the tissue and its appearance in EVs at 24 h prompts speculation that EV
release may provide a mechanism to remove oxidatively modified protein, which
is highly toxic to cells.
The increased levels of protein-bound 4HNE in circulating EVs suggest an
oxidative stress-related mechanism in the tissues producing the EVs. This
finding, coupled with the proteomic analysis, which identified a set of proteins
with tissue-specific EVs, implicates tissue injury. The proteomic profiling revealed
TfR1 and MHC-I as uniquely expressed proteins in SAL_EVs but not in
DOX_EVs. TfR1 is a membrane protein for transferrin-iron complex uptake in
erythrocyte precursors. This protein is released in the form of exosomes during
erythrocyte

maturation
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The

disappearance of TfR1 from DOX_EVs is consistent with the myelosuppressive
effect of DOX, which peaks by day 3 post-treatment and is associated with a
90% reduction of total bone marrow cells [154]. MHC-I, on the other hand, is
required for selection of naïve CD8+ T lymphocytes, which occurs in the thymus
and other immune-related tissues, and for presentation of intracellular peptideantigens to cytotoxic (CD8+) T lymphocytes [155]. Moreover, peripheral MHC-I is
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also involved in the repopulation of CD8+ T cells outside the thymus [156].
Previous reports from our group showed that acute DOX treatment caused
thymus atrophy and subsequent loss of T cell maturation in the thymus [157]. In
the present study, loss of MHC-I from DOX_EVs suggests an interference with
the maintenance of T cell survival in peripheral blood, potentiating the
immunosuppressive effect of DOX on any adaptive immune response. In contrast
to SAL_EVs, proteins uniquely expressed in DOX_EVs are related to the
oxidative and metabolic stress response. Hp is an acute-phase protein, released
predominantly from liver. Hp functions as an antioxidant by binding to extracorpuscular hemoglobin during hemolysis. This action impedes heme-iron
exposure to an oxygenated environment, averting the Fenton reaction, which
leads to ROS production [158].
Metabolic alteration also occurs in many tissues after DOX treatment.
Gene expression [159] and metabolomics [160] analyses of DOX-treated cardiac
tissue show that myocardial metabolism switches from fatty acid oxidation to
anaerobic glycolysis. Glycogenolysis provides alternative source of glucose
derived from glycogen breakdown during stress conditions. Glycogenolysis is
regulated by one of 3 isoforms of GP in a tissue-specific manner. The brain
isoform, encoded by the PYGB gene, is enriched in heart and brain tissues. The
muscle isoform, encoded by PYGM gene, and the liver isoform, encoded by
PYGL gene, are enriched in skeletal muscle and liver, respectively [161]. The
current study demonstrates that all three GP isoforms are expressed in
DOX_EVs. Interestingly, PYGB, PYGM, and PYGL were depleted from heart,
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skeletal muscle, and liver, respectively, after DOX treatment, suggesting that the
EV-encapsulated PYGB, PYGM, and PYGL were released from those particular
tissues. However, we did not observe a decrease of PYGB in the brain tissues of
DOX-treated mice. Because DOX does not cross the blood-brain barrier, our
data indicate that EV-associated GPs are released from the tissues that are
directly affected by the drug. Therefore, the data suggest that EVs containing a
specific GP may be an indicator of the injury of direct target tissues from DOX,
specifically glycogenolysis dysfunction, which might be an early sign of tissue
injury during chemotherapy.
The strong association of EV release with oxidative stress was shown in
the co-immunoprecipitation of 4HNE-adducted EVs with GP, suggesting that
those EVs were released from tissues experiencing high oxidative stress.
Moreover,

mice

with

higher

antioxidant

capacity,

such

as

MnSOD-

overexpressing mice or MnP-pretreated mice, released lesser amounts of EVs
following DOX treatment. Furthermore, a clinically approved cardioprotective
drug that has antioxidant effects, DRZ, also reduced the amount of EV release
from heart tissue. However, the effect of DRZ on EV release was weaker than
that of MnP, which might be explained by the stronger antioxidant effects of MnP
over DRZ. This finding might warrant a clinical trial comparing cardioprotective
effect of MnP vs. DRZ against DOX. Moreover, the relationship between 4HNEadducted EVs and the level of tissue oxidative stress can be utilized in
personalized medicine, where we can use EVs to predict antioxidant capacity
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against chemotherapy of individual patients and adjust the dose of chemotherapy
to avoid normal tissue injury.
Compared to conventional serum biomarkers, EV-associated GP can
detect chemotherapy-induced tissue injury earlier, which would allow the initiation
of preventive intervention to preserve normal tissue function before cell death
occurs. However, because our study is based on normal mice without cancer,
our result is only valid for predicting tissue injury in patients that no longer have
tumors, such as long-term cancer survivors. In patients that still have tumors, EVassociated GP may also be released from the tumor itself. Further studies in
tumor-bearing mice should be performed to confirm this speculation.
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CHAPTER THREE. OXIDIZED EXTRACELLULAR VESICLES ARE IMMUNE
MODULATORS IN CHEMOTHERAPY-INDUCED NORMAL TISSUE INJURY.
Overview
DOX is known to cause oxidative stress and inflammation in heart tissue
as well as in the systemic circulation. Extracellular vesicles (EVs) are released
from cells during oxidative stress and send oxidized molecules into the circulation
as a compensatory mechanism that prevents cellular proteotoxicity. Immune cells
can sense oxidized molecules in EVs as molecular patterns associated with
damage, which leads to immune activation. By using a mouse model of DOX induced tissue injury, we previously found that EVs are released from target
tissues of DOX-treated animals, including the heart and the liver. Here, we
compared the effects of EVs from cardiomyocytes and hepatocytes on changes
in macrophage phenotype (phenotype switching) in a cell culture system. EVs
from H9c2 cardiomyocytes (H9c2 EVs) and FL83b hepatocytes (FL83b EVs)
have different levels of protein-bound 4-hydroxynonenal and, thus, different
immunogenic effects on macrophages. H9c2 EVs but not FL82b EVs induce
macrophages to exhibit both pro-inflammatory and anti-inflammatory phenotypes,
which are mediated by NFκB activation and upregulation of anti-oxidant enzymes
via Nrf2 activation. This macrophage phenotype was previously described as the
Mox macrophage, which is expressed when the macrophages are challenged
with oxidized phospholipids. DOX enhances the effects of H9c2 EVs but not
FL83b EVs. Mechanistically, the different functions of H9c2 EVs and FL83b EVs
on macrophage phenotype switching are due to their different effects on
77

Thioredoxin 1, which is a redox- sensitive protein that regulates the immune
response under oxidative stress. Our findings shed light on the role of EVs as a
redox active mediator of immune response during chemotherapy.
Introduction
DOX is one of the most potent chemotherapeutic agents but its efficacy is
limited by severe side effects to normal tissues. The toxicity of DOX is not limited
to the acute phase, when the drug is present in the body, but it lasts for many
decades after the treatment cessation. The reason for that is because of the
continued propagation of oxidative stress from oxidized toxic molecules. To
maintain cellular homeostasis, cells have developed a variety of mechanisms to
remove oxidized toxic molecules including ubiquitin-proteosome degradation,
autophagy and mitophagy. However, under DOX-induced severe oxidative
stress, these mechanisms are compromised [34,88]. Thus, the cells are forced to
remove those toxic molecules by alternative pathways.
Extracellular vesicles (EVs) are small membrane-encapsulated structures
that are released from the cell under normal and pathological conditions. Several
protein machineries in EV formation are utilized for in oxidized molecule sorting
but instead of being degraded inside the cells, those molecules are exported out
of the cells and mediate intercellular communication. Accumulating evidence has
revealed the important role of EVs in the context of oxidative stress. Many of
them are related to the transfer of damage associated molecular patterns
(DAMPs) to activate immune cells [71,74-76]
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Macrophages are mononuclear phagocytic cells that mediate the innate
immune response by recognizing microbial and endogenous danger- signaling
molecules [162]. Upon sensing environmental stimuli, macrophages can be
polarized into different phenotypes with distinct sets of gene expression, cytokine
release, cellular metabolism, and biological functions. Generally, macrophage
polarization is classified into two phenotypes: pro-inflammatory (M1) and antiinflammatory (M2) macrophages. M1 macrophages express and release proinflammatory cytokines including TNF alpha, IL-1 beta, IL-6, and generate
reactive oxygen or reactive nitrogen species in order to eliminate microbes as
well as cell debris. In contrast, M2 macrophages release anti-inflammatory
cytokines such as IL-10, and TGF beta that inhibit the effect of M1 thus limiting
tissue inflammation and promote tissue repair. In physiologic conditions, M1 and
M2 activities are strictly regulated. Severe pro-inflammatory immune responses
can lead to a secondary cytotoxicity and tissue destruction while excessive antiinflammatory responses can lead to tissue fibrosis. Tissue injury induced by DOX
is not limited to the direct effects on the target tissues, but also involves the
indirect effects from inflammation initiated by the innate immune response to the
endogenous danger signals [101,163]. Moreover, the inflammatory cytokines
generated locally in the tissues can enter the circulation and have an effect on
distant organs.
Previously, we identified the heart and liver as the major tissues that
contribute to circulating EVs after DOX treatment. However, the function of EVs
released from these two organs that have different levels of oxidative stress has
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not yet been investigated. The cardiomyocyte is the most sensitive cell type for
DOX-induced oxidative stress [164] making cardiomyopathy the most concerning
side effect in cancer patients receiving DOX, as well as other chemotherapeutic
agents that involve reactive oxygen species (ROS) generation. Unlike cardiac
dysfunction, liver dysfunction is rarely observed in DOX-treated patients [165].
The reason for this might be due to an enrichment in antioxidant enzymes [166]
and drug transporters in the liver [167].
Here, we demonstrate that cardiomyocytes and hepatocytes release EVs
with different oxidized protein levels and have differential effects on
macrophages Thioredoxin 1 (TRX1), a redox regulator, regulates macrophage
polarization in response to EVs by controlling the redox sensitive transcription
factors NFκB and Nrf-2. The findings of this study provide insight into the
intercellular communication between injured cells and macrophages coordinated
by EVs in response to DOX treatment and provide a new target for treatment of
DOX-induced inflammation.
Materials and Methods
Cell Culture and Treatment
H9c2 embryonic rat normal cardiomyocytes, FL83b fetal mouse normal
hepatocytes, Raw264.7 Abelson murine leukemia virus transformed mouse
macrophage, and NR8383 rat alveolar macrophage cell lines were obtained from
the American Type Culture Collection (Manassas, VA). H9c2 cells were
maintained in DMEM low glucose supplemented with 10% FBS, 1%
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penicillin/streptomycin, 1 mM pyruvate, 25 mM HEPES, 2 mM glutamine, 1%
non-essential amino acids. FL83b cells were maintained in F12 medium
supplemented with 10% FBS and 1% penicillin/streptomycin. RAW264.7 cells
were maintained in DMEM high glucose supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. NR8383 cells were maintained in
Ham’s F12K medium supplemented with 15% heat inactivated FBS, 2 mM Lglutamine, and 1.5 g/L sodium bicarbonate. The absence of mycoplasma
contamination was confirmed in all cell lines.
For macrophage activation, RAW264.7 cells were seeded at a density of
5x105 cells/well in 6 well-plate overnight and incubated with FBS free media
supplemented with 20 µg of H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, FL83b
DOXEV, or an equal volume of PBS as a vehicle for 24 h. The conditioned media
were then collected and were frozen at -80º C until used.
Cell Viability Test
The sensitivity to DOX toxicity of H9c2 and FL83b cells was measured
with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium
(MTT) reduction assay. This assay relies on electron transfer from NADH and
NADPH to MTT, which is achieved by oxidoreductase enzyme activity in viable
cells [168]. The final product is the insoluble purple colored formazan. In this
experiment, H9c2 or FL83b cells were seeded in 96-well plates at the density
1000 cells/100 µl/well. The next day the cells were exposed to 0.5 μM of DOX for
24 hours. Cells were then washed with PBS and 30 μl of MTT solution (5 mg/ml
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in PBS) was added to each well and incubated for 1 hour. Then, 70 μl of 50%
DMSO and 50% SDS was added to solubilize the formazan crystals. Absorbance
was determined at 540 nm by SpectraMax Plus 384 microplate reader (Molecular
Devices, San Jose, CA). DOX cytotoxicity was expressed as the percent viability
in treated cells relative to the non-treated control.
EV Isolation and Quantitation
H9c2 and FL83b were treated or not treated with 0.5 μM DOX in 20 ml
growing media for 1 h followed by washing with 3 x 10 ml PBS. The media was
changed to EV-free growing media and incubated for 48 hours before the
conditioned media collection. The conditioned media were filtered through 0.8 μm
syringe filters to exclude vesicles larger than 0.8 μm, which are typically the
apoptotic bodies. The filtered conditioned media were stored at -80 ºC until use.
EVs were isolated by an affinity-based membrane method using exoEasy
maxi kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
All types of EVs including exosomes, microvesicles, and apoptotic bodies were
bound to the spin column and eluted to obtain EV products. The conditioned
media were thawed at room temperature and 32 ml of the media were then
mixed 1:1 with buffer XBP and applied onto the affinity spin column allowing EV
binding to the membrane. After centrifugation at 500 x g for 1 min, the flowthrough was discarded. XWP buffer was added to the column and centifuged at
5000 x g for 5 min to wash off contaminating proteins and residual buffer. Buffer
XE was then applied onto the membrane and centrifuged at 500 x g, 5 min to
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elute EV from the column. The eluated was applied to the column again and
centrifuged at 5000 x g, 5 min. Since XE buffer contains primarily inorganic salts
that are toxic to cells, buffer exchange with PBS were performed using 3 kDa
Amicon Ultra-15 Centrifugal Filter units (Millipore Sigma, Burlington, MA). The
amount of EVs was evaluated by bicinchoninic acid assay (Thermo Fisher
Scientific, Waltham, MA).
4HNE Adducted Protein Measurement
EVs from H9c2 non-treated (H9c2 NTEV), H9c2 DOX-treated (H9c2
DOXEV), FL83b non-treated (FL83b NTEV), and FL83b DOX-treated (FL83b
DOXEV) were lysed with radioimmunoprecipitation assay (RIPA) buffer and
mixed with an equal volume of Laemmli buffer. Equivalent protein samples (250
ng) were then loaded on nitrocellulose membrane using Bio-Dot SF microfiltration
apparatus (Bio-Rad). The membranes were allowed to air dry overnight. The next
day, the membranes were blocked with blocking buffer for 2 h followed by
incubation with anti-4HNE antibody (1:5000 dilution) for 1 h on an orbital shaker.
After washing with TBST three times, the membranes were incubated with
IRDye® 800CW donkey anti-rabbit (1:15,000 dilution) for 1 h. Then, the
membranes were washed and allowed to air dry. The 4HNE-adducted protein
bands were visualized using Odyssey scanner (LI-COR).
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
For macrophage activation, RAW264.7 cells were seeded at the density of
1x106 cells/well in 6 well-plate overnight and were incubated with 20 µg of EVs
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from non-treated H9c2 cells, DOX-treated H9c2 cells, non-treated FL83b cells,
and DOX-treated FL83b cells for 6 or 24 hours. RNA was isolated from the cells
using the MagNA Pure Compact RNA Isolation kit (Roche, Risch-Rotkreuz,
Switzerland). The RNA integrity was evaluated using the Agilent 2100
Bioanalyzer System (Santa Clara, CA). The mRNAs were reverse transcribed to
cDNA using the first strand cDNA Synthesis Kit (Roche). The Nanodrop
Spectrophotometer (Thermo Fisher Scientific) was used to measure cDNA
concentration. Quantitative real-time PCR was performed using a LightCycler
480 Real-Time PCR System (Roche) with gene-specific primers. All primers were
purchased from Invitrogen. Primer sequences for mouse genes were as follows:
Mouse Tnf 5’-CCTGTAGCCCACGTCGTAGC-3’ (Forward) and 5’AGCAATGACTCCAAAGTAGACC-3’ (Reverse);
Mouse Il1b 5’-GCACTACAGGCTCCGAGATGAAC-3’ (Forward) and 5’TTGTCGTTGCTTGGTTCTCCTTGT-3’ (Reverse);
Mouse IL-6 5’- GACAAAGCCAGAGTCCTTCAGAGAG-3’ (Forward) and 5’CTAGGTTTGCCGAGTAGATCTC-3’ (Reverse);
Mouse iNOS 5’-TTTGCTTCCATGCTAATGCGAAAG-3’ (Forward) and 5’GCTCTGTTGAGGTCTAAAGGCTCCG-3’ (Reverse);
Mouse IL-10 5’-ATTTGAATTCCCTGGGTGAGAAG-3’ (Forward) and 5′CACAGGGGAGAAATCGATGACA-3′ (Reverse);
Mouse HO-1 5′-GGTGATGGCTTCCTTGTACC-3′ (Forward) and 5′GGTGATGGCTTCCTTGTACC-3′ (Reverse);
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Mouse PRDX1 5’-ACACCCAAGAAACAAGGAGGATT-3’ (Forward) and 5’CAACGGGAAGATCGTTTATTGTTA-3’ (Reverse);
Mouse Actb 5’-TGGAATCCTGTGGCATCCATGAAAC-3’ (Forward) 5’TAAAACGCAGCTCAGTAACAGTCCG-3’ (Reverse);
Rat Il1b 5’- GCAATGGTCGGGACATAGTT-3’ (Forward) 5’AGACCTGACTTGGCAGAGGA-3’ (Reverse);
Rat Nos2: 5’-TAGTCAACTACAAGCCCCACG-3’ (Forward) 5′GTGAGGAACTGGGGGAAACC-3′ (Reverse);
Rat Il10 5’GTTGCCAAGCCTTGTCAGAAA-3’ (Forward) 5’TTTCTGGGCCATGGTTCTCT-3’ (Reverse);
Rat Actb 5’-AGGCATCCTCACCCTGAAGTA-3’ (Forward) 5’CACACGCAGCTCATTGTAGA-3’ (Reverse).
The PCR cycles were as follows: initial denaturation 10 min at 95ºC, 45
cycles of 15 sec at 95ºC, 30 sec at 60 ºC, and 30 sec at 72ºC.
Multiplex Cytokines Array
V-PLEX mouse cytokine immunoassay kit (Meso Scale Diagnostics,
Rockville, MD) was used to measure TNF alpha, IL-1 beta, IL-6, and IL-10 (Meso
Scale Diagnostics, Rockville, MD). Mouse TGF-beta 1 DuoSet ELISA (R&D
systems, Minneapolis, MN) was used to measure TGF beta 1. All assays were
performed according to the manufacturer’s protocol. All standards and samples
were measured in duplicate or triplicate.
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Nitric Oxide (NO) Measurement
RAW264.7 cells were treated with FBS-free DMEM without phenol red,
and supplemented with 20 µg of EVs or an equal volume of the vehicle control.
The conditioned media were collected at 24 hours post-treatment. Since NO is
unstable and completely oxidized in biological fluid, we measured the
accumulation of the stable oxidized products of NO, nitrite and nitrate, in the
conditioned media using Nitrate/Nitrite colorimetric assay kit (Cayman, Ann
Arbor, MI). Briefly, the conditioned media was incubated with nitrate reductase to
convert nitrate to nitrite. Then, Griess reagents were added to react with total
nitrite and generate deep purple azo compound. The change in color was
evaluated by reading the absorbance at 540 nm using a microplate reader
(Molecular Device, San Jose, CA). The concentration of nitrate/nitrite in samples
was calculated from a standard curve generated using known concentration of
nitrate.
Mitochondrial and Glycolysis Stress Test
RAW264.7 cells were seeded into a 96 well plate (Seahorse Bioscience,
North Billerica, MA) at the density of 20,000 cells/well for both the mitochondrial
and glycolysis stress tests. The next day, the cells were treated with 20 µg/ml of
EVs or an equal volume of PBS for 24 hours prior to the test. For the
mitochondrial stress test, oxygen consumption rate (OCR) was determined using
the Seahorse XF-96 analyzer (Seahorse Bioscience). OCR was measured at
baseline (Basal OCR) followed by the sequential addition of oligomycin (1 µM) to
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inhibit ATP synthase, FCCP (1 µM) uncoupler to permeabilize the inner
mitochondrial membrane and promote maximum electron flow, or rotenone (1
µM) / antimycin (1 µM) to inhibit complex I and complex III, respectively. ATPlinked OCR was calculated by subtracting the OCR after oligomycin treatment
from the basal OCR. The spare respiratory capacity was calculated by
subtracting the basal OCR from the maximal OCR after FCCP treatment. For the
glycolysis stress test, the extracellular acidification rate (ECAR) was determined
with the Seahorse XF-96 analyzer. ECAR was measured at baseline followed by
the sequential addition of glucose (10 mM), Oligomycin (1 µM), and 2deoxyglucose (50 mM). Basal glycolysis was calculated by subtracting the ECAR
measurement post-2-deoxyglucose addition from the ECAR measurement postGlucose addition. The glycolytic reserve capacity was calculated by subtracting
the post-Oligomycin measurement from the post-Glucose measurement.
Western Blot Analysis
For EVs western blots, EVs suspension in PBS (0.5 µg/µl) was lysed with
RIPA buffer containing protease inhibitor and sonicated for 3 x 30 sec using a
water sonicator. For western blots of macrophage proteins, cells were lysed by
incubating with RIPA buffer containing protease inhibitor on ice for 30 min.
Protein concentrations were determined using bicinchoninic acid assay. SDS
polyacrylamide gels (8-15%) were loaded with 50 µg of lysed EVs or 40 µg of
whole cell lysates and electrophoresis was performed at 100 V for 2 h. The
proteins were transferred onto nitrocellulose membranes. After blocking with
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 h, the
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membranes were incubated overnight with primary antibodies

at 4ºC. The

following primary antibodies were used: anti-Alix, anti-CD81, anti-caspase-1,
anti-HDAC1, anti-Lamin A/C (Santa Cruz Biotechnology, Dallas, TX), anti-NLRP3
(MyBioSource, San Diego, CA), anti-IL-1 beta (PromoCell GmbH, Heidelberg,
Germany), anti-beta actin (Sigma-Aldrich, St. Louis, MO), anti-MnSOD (Upstate
Biotechnology, Waltham, MA), The membranes were washed three times with
TBST buffer and were incubated with IRDye 800 CW donkey anti-goat for antiAlix, donkey anti-rabbit for anti-CD81, anti-NLRP3, anti-caspase-1, anti-IL-1 beta,
and anti-MnSOD, or goat anti-mouse for beta-actin, anti-HDAC1, and anti-Lamin
A/C for 1 h at room temperature. After washing three times, the membranes were
air dried and the protein bands were visualized using the Odyssey scanner (LICOR).
NFκB and Nrf-2 DNA Binding Activity
To measure NFκB and Nrf-2 transcription factor activity, DNA binding
ELISA was performed using TransAM NF-κB and Nrf-2 kit (Active motif,
Carlsbad, CA) according to the manufacturer’s protocol. Breifly, nuclei from
RAW264.7 cells were extracted by nuclear extract kit (Active motif). Then, the
nuclear extract was added onto the oligonucleotide-coated well and incubate for
1 hour. After the washing step, the primary antibody for NF-κB (p65) or Nrf-2 was
added and incubated for 1 hour. Then, the plates were washed and incubated
with the HRP-conjugated secondary antibody for 1 h. The color was developed
by the developing solution and the absorbance was read at 450 nm.
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Thioredoxin 1 Redox Western
Reduced and oxidized forms of thioredoxin 1 (TRX1) in nuclear and
cytoplasmic portions of RAW264.7 cells treated with EVs were detected as
described previously [169-171] After incubation of EVs for 24 hours, the cells
were washed with ice-cold PBS and lyse with hypotonic solution supplemented
with protease inhibitor and 50 mM iodoacetic acid (IAA). The lysate was
centrifuged at 16,100 g for 2 min and the supernatant was collected as the
cytoplasmic fraction. The nuclear pellet was lysed with G-lysis buffer
supplemented with protease inhibitor and IAA. Iodoacetic acid (IAA) was used to
modify the thiol group resulting in one negative charge addition per one
modification. Microspin G-25 columns were used to remove excessive IAA. After
the derivatization, TRX1 redox forms were separated by charge using native
polyacrylamide gel electrophoresis and were detected using anti-TRX1 antibody
(AdipoGen Life Sciences, San Diego, CA) as a primary antibody and IRDye®
800CW donkey anti-Rabbit as a secondary antibody. The protein bands were
visulized using Odyssey scanner (LI-COR, Lincoln, NE). The band intensities
were assessed using Image Studio 5.x software (LI-COR)
Statistical Analysis
Results are presented as the mean ± standard deviation (SD) or standard
error of the mean (SEM) as indicated in the figure legend. Analysis of variance
(ANOVA) was used for comparison of study endpoints including 4HNE slot blot,
western blot, and Trx1 redox western, EVs, and other parameters in the
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macrophages from cardiomyocytes and hepatocytes. Pairwise comparisons
were performed from the ANOVA model between vehicle versus treated and
differences between H9c2 NTEV vs H9c2 DOXEV, FL83b NTEV vs FL83b
DOXEV, H9c2 NTEV vs FL83b NTEV, and H9c2 NTEV vs FL83b
DOXEV. Adjusted p-values due to multiple testing were calculated using the
Holm’s method. A value of P<0.05 was considered significant. The SAS system
version 9.4 was used for data analysis. Excel and GraphPad Prism were used for
graphing.

Results
DOX induced cardiomyocytes—but not hepatocytes—release EVs with
higher levels of protein-bound 4HNE.
By measuring cell viability after 24 h of DOX treatment, the result shows
that the viability of H9c2 cells decreased by 13 % while FL83b cell viability was
similar to the non-treated control. These data indicate that H9c2 cells are more
sensitive to DOX than FL83b cells (Figure 3.1A). The quantity of EVs, as
indicated by the level of EV protein, reveals that H9c2 and FL83b cells release
equal amounts of EVs per equal number of cells under normal conditions. DOX
induced at least a 4-fold increase in EV release from both H9c2 and FL83b cells
(Figure 3.1B). However, with an equal amount of EV protein, EVs from H9c2
cells had more protein-bound 4HNE than EVs from hepatocytes. Moreover,
comparisons between DOX-treated EVs (DOXEV) and non-treated EVs (NTEV)
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showed that the H9c2 DOXEV contained more 4HNE adducted proteins than the
H9c2 NTEV. However, there was no difference between FL83b DOXEV and
FL83b NTEV. (Figure 3.1C). These data suggest that DOX induces
cardiomyocytes but not hepatocytes to release EVs with higher level of oxidized
proteins.

Figure 3.1

Comparison of DOX toxicity, the level of EVs and

the level of 4HNE protein adduction in the EVs released from
cardiomyocytes and hepatocytes
(A) Percentage of surviving H9c2 cells and FL83b cells after 0.5
µM DOX treatment for 24 h (green bars) compared to non-treated
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control (black bars). * p < 0.05 vs non-treated cells (B) Amount of
EVs released from one million cells in non-treated H9c2, DOXtreated H9c2, non-treated FL83b, or DOX-treated FL83b cells. * p <
0.05 vs non-treated cells (C). Western blots of EVs markers: Alix
and CD81 in EVs derived from non-treated H9c2 (H9c2 NTEV),
DOX-treated H9c2 (H9c2 DOXEV), non-treated FL83b (FL83b
NTEV), or DOX-treated FL83b (FL83b DOXEV). (D) The levels of
4HNE protein adduction in H9c2 NTEV, H9c2 DOXEV, FL83b
NTEV, or FL83b DOXEV. Data represent the mean of band
intensities relative to H9c2 NTEV ± SD of 5 independent
experiments * p < 0.05 vs H9c2 NTEV.

Differential effects of H9c2 EVs and FL83b EVs on M1 and M2 polarization.
To investigate the effect of EVs on macrophage polarization, RAW264.7 cells
were treated with EVs and gene expression of M1 markers including TNF alpha,
IL-1 beta, IL-6 and iNOS, as well as M2 marker IL-10 were measured at 6 h and
24 h after treatment. To select the appropriate dose of EVs for the whole study,
RAW264.7 cells were treated with various doses of H9c2 NTEV, H9c2 DOXEV,
FL83b NTEV, and FL83b DOXEV and TNF alpha gene expression was
measured. The result shows that both H9c2 NTEV and H9c2 DOXEV
upregulated TNF alpha in dose-dependent manner. However, the significant
difference between H9c2 NTEV and H9c2 DOXEV were observed at 20 µg
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treatment (Supplementary figure 3.1A). In contrast, with the similar various
concentration of EV treatment, neither FL83b NTEV nor FL83b DOXEV induced
TNF alpha gene expression (Supplementary figure 3.1B).

Supplementary figure 3.1

Comparison of the effect of

various doses of EVs on macrophage TNF alpha gene
expression
(A) TNF alpha mRNA levels in RAW264.7 cells treated with 0, 10,
20, and 40 µg of H9c2 NTEV (blue) or H9c2 DOXEV (red), Data
represent the mean ± SD of 3 independent experiments * p < 0.05
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vs 0 µg, $ p < 0.05 vs 10 µg, # p < 0.05 vs 20 µg, ¶ p < 0.05 vs
H9c2 NTEV. (B) TNF alpha mRNA levels in RAW264.7 cells
treated with 0, 20, and 40 µg of FL83b NTEV (blue) or FL83b
DOXEV (red) Data represent the mean ± SD of 3 independent
experiments
By treatment with 20 µg of EVs, the data show that H9c2 EV but not
FL83b EV induce M1 and M2 polarization as evidenced by the increase in both
M1

and

M2

markers.

DOX

treatment

promoted

both

M1

and

M2

immunostimulatory effects in H9c2 EVs but not in FL83b EVs (Figure 3.2A-3.2J).
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Figure 3.2

Cardiomyocyte-derived EVs but not hepatocyte-

derived EVs promote both M1 and M2 macrophage gene
expression. Cardiomyocyte EV levels was potentiated by DOX
treatment.
(A-H) Graphs demonstrate the fold change of M1 macrophage
gene expression for TNF alpha (A, B), IL-6 (C, D), IL-1 beta (E, F),
and iNOS (G, H) in RAW264.7 cells with 6 and 24 hour incubation
of EVs from non-treated and DOX-treated H9c2 cells, and non95

treated and DOX-treated FL83b cells. (I-J) Fold change of M2 gene
IL-10 in RAW264.7 macrophages with 6 and 24 hour incubation of
EVs from H9c2 non-treated, H9c2 DOX-treated, FL83b non-treated
and FL83b DOX-treated. Data represent the mean ± SD of 3-5
independent experiments * p < 0.05 vs vehicle control, # p < 0.05
vs H9c2 NTEV

The M1 and M2 effects of EVs on macrophage gene expression were
confirmed by the increase in pro- and anti-inflammatory cytokines release into
the conditioned media at 24 h post EV treatment (Figure 3.3A-3.3E), as well as
by the increase in nitric oxide (NO) production (Figure 3.3F). The NO generation
is specific to NOS expression because it is suppressible by N(G)-Nitro-L-arginine
methyl ester (L-NAME), which is a competitive inhibitor of NOS.
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Figure 3.3

Cardiomyocyte-derived EVs but not hepatocyte-derived

EVs promote both pro-inflammatory and anti-inflammatory cytokine
release as well as nitric oxide production from macrophage. The
effect was potentiated by DOX treatment
(A-C) Levels of pro-inflammatory cytokines TNF alpha, IL-1 beta,
IL-6 in RAW264.7 cells treated for 24 hours with vehicle, EVs from
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H9c2 non-treated EVs (H9c2 NTEV), H9c2 DOX-treated EVs (H9c2
DOXEV), FL83b non-treated EVs (FL83b NTEV) and FL83b DOXtreated EVs (FL83b DOXEV). (D-E) Levels of anti-inflammatory
cytokines; IL-10 and TGF beta in RAW264.7 cells treated for 24
hours with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and
FL83b DOXEV. (F) Level of Nitrite/Nitrate as a parameter of NO
production in RAW264.7 cell treated with vehicle, H9c2 NTEV,
H9c2 DOXEV, FL83b NTEV, and FL83b DOXEV. L-NAME was
used as a negative control as well as the inhibitor of H9c2 EV effect
on NO production. L-NAME = N(G)-Nitro-L-arginine methyl ester,
Data represent the mean ± SEM of 4 independent experiments * p
< 0.05 vs vehicle control, # p < 0.05 vs H9c2 NTEV

The immunostimulatory effect of H9c2 EVs was not due to species
differences between rat cardiomyocytes and mouse macrophages as we
observed similar results with NR8383 rat macrophages (Supplementary figure
3.2).
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Supplementary figure 3.2 Gene

expression

of

NR8383

rat

macrophages after EV treatment for 24 h
(A) Bar graphs represents fold change of IL-1β, iNOS (B) and IL-10
(C) gene expression measured by RT-PCR of macrophage treated
with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and FL83b
DOXEV. Data represent the mean ± SD of 3 independent
experiments * p < 0.05 vs vehicle, # p < 0.05 vs H9c2 NTEV
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Differential effects of H9c2 EVs and FL83b EVs on macrophage
metabolism.
M1 and M2 polarizations are supported by the metabolic pathways that
macrophages use to produce energy [172]. Upon M1 activation, aerobic
glycolysis is induced due to the ineffective enzymes in the Kreb’s cycle. On the
other hand, M2 macrophages utilize mitochondrial oxidative phosphorylation
(OXPHOS) to make ATP, and the intermediates from OXPHOS will help with
tissue repair process [173]. Here, we observed that EVs induce the metabolic
shifts in macrophages. Data from the mitochondrial stress and glycolytic stress
tests show that EVs from DOX-treated H9c2 cells significantly suppressed basal
OCR (Figure 3.4A and 3.4B) and enhanced glycolysis of macrophages (Figure
3.5A and 3.5B), which is in support of the metabolic process expected for M1
polarization. EVs from non-treated H9c2 cells also suppressed basal OCR and
increased glycolysis but the levels did not reach statistical significance. However,
EVs from both non-treated and DOX-treated H9c2 cells have no effect on
glycolytic reserved capacity (Figure 3.5C). In contrast, EVs from FL83b did not
have any effects on basal OCR, glycolysis, and glycolytic reserved (Figure 3.4A3.4B, 3.5A-3.5C) but they induced higher mitochondrial spare respiratory
capacity (Figure 3.4C). These data suggest that EVs from hepatocytes did not
induce either M1 or M2 polarization but they do enhance mitochondrial
metabolism under stress conditions.
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Figure 3.4

Differential effects of H9c2_EVs and FL83b_EVs

on mitochondrial respiration
(A) Kinetic graph of OCR at baseline and after oligomycin, FCCP,
and rotenone/antimycin treatment of macrophages incubated with
vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV, and FL83b
DOXEV. (B) Bar graph represents the average of basal OCR
calculated from graph A (C) Bar graph represents the average of
Spare Respiratory Capacity calculated from graph A. Data
represent the mean ± SEM of 3 independent experiments * p < 0.05
vs vehicle
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Figure 3.5

Differential effects of H9c2_EVs and FL83b_EVs

on glycolysis
(A) Kinetic graph of ECAR at baseline and after glucose,
oligomycin, and rotenone/antimycin treatment of macrophages
incubated with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b NTEV,
and FL83b DOXEV. (B) Bar graph represents the average of basal
glycolysis calculated from graph A (C) Bar graph represents the
average of Glycolytic reserve calculated from graph A. Data
represent the mean ± SEM of 3 independent experiments * p < 0.05
vs vehicle
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Differential effects of H9c2 EVs and FL83b EVs on NFκB and Nrf-2
transcription activity.
Macrophage polarization is known to be regulated by redox signaling.
NFκB and Nrf-2 are two interconnected redox sensitive transcription factors that
control opposite immune responses during oxidative stress [174]. NFκB
activation leads to the upregulation of pro-inflammatory target genes such as
TNF alpha, IL-1 beta, IL-6 and chemokines. On the contrary, Nrf-2 activation
upregulates anti-oxidant genes, which remove ROS and prevent inflammation
[121]. Nrf-2 also has anti-inflammatory effect independent of ROS detoxification.
Nrf-2 can directly suppress inflammation by binding to the promotor region of proinflammatory cytokine genes such as IL-6 and IL-1 beta and inhibit RNA
polymerase II recruitment to the transcription site [122]. By measuring the DNA
binding activity of NFκB and Nrf2 in RAW264.7 macrophages treated with EVs,
we found that H9c2 EVs but not FL83b EVs induced NFκB and Nrf-2 DNA
binding activity. Similar to the gene expression results, DOX potentiated the
effect of H9c2 EVs on NFκB and Nrf-2 activation but had no effect on FL83b EVs
(Figure 3.6A and 3.6B). The activation of Nrf-2 was confirmed by upregulation of
antioxidant gene expression, peroxiredoxin 1 (PRDX1) and heme oxygenase 1
(HO-1) (Figure 3.6C and 3.6D).
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Figure 3.6

Cardiomyocyte-derived EVs but not hepatocyte-

derived EVs enhanced NFκB and Nrf-2 transcription factor
activity. The effect was potentiated by DOX.
(A) NFkB DNA binding activity and (B) Nrf2 DNA binding activity in
macrophages treated with vehicle, H9c2 NTEV, H9c2 DOXEV,
FL83b NTEV, and FL83b DOXEV. (C, D) Fold change of antioxidant gene expression; PRDX1 (C) and HO-1 (D) after 24 hour
treatment of RAW264.7 cells with vehicle, H9c2 NTEV, H9c2
DOXEV, FL83b NTEV, and FL83b DOXEV. Data represent the
mean ± SD of 3 independent experiments* p < 0.05 vs vehicle, # p
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< 0.05 vs H9c2 NTEV, PRDX1 = peroxyredoxin1, HO-1 = heme
oxygenase-1

Differential effects of H9c2 EVs and FL83b EVs on NLRP3 inflammasomes.
The inflammasome is an intracellular complex that mediates maturation and
re le a s e o f IL -1 b e ta a n d IL -1 8 fo r th e in n a te im m u n e re s p o n s e . T h e
inflam m asom e com plex is com posed of a nucleotide-binding oligomerization
domain-like receptor containing protein (NLRP), apoptosis-associated speck like
protein containing caspase recruitment domain (ASC), and inactive IL-1
converting enzyme called pro-caspase-1 [175]. NLRP is a pattern recognition
receptor that can sense pathogen-associated molecular patterns (PAMPs)
present in exogenous microorganisms or damage-associated molecular patterns
(DAMPs) formed by endogenous damaged cells. NLRP3 is the most
characterized NLRP. NLRP3 activation requires both a priming signal to induce
gene expression of NLRP3 itself, pro-IL-1 beta and pro-IL-18 via enhancing
N F κ B tra n s c rip tio n a c tiv ity , as well as an activation signal from PAMPs or
DAMPs to induce inflammasome complex formation [176,177]. Once the
complex is formed, pro-caspase 1 is converted to active caspase-1, which further
cleaves pro-IL 1 beta and IL-18 into their mature active forms [178].
Because we found that IL-1 beta release was induced by H9c2 EVs and
potentiated by DOX, we investigated if the release of IL-1 beta is due to
inflammasome activation. Western blots of inflammasome components in
RAW264.7 cells treated with EVs shows that only H9c2 EVs but not FL83b EVs
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activate NLRP3 inflammasomes as evidenced by an increase in NLRP3, procaspase 1, cleaved caspase-1, and cleaved IL-1 beta. Comparing between H9c2
NTEV and H9c2 DOXEV, DOXEV induced inflammasome activation slightly
more than NTEV (Figure 3.7).

Figure 3.7

NLRP3

inflammasome

was

activated

by

cardiomyocyte- but not hepatocyte-derived EV treatment. DOX
enhance the effect of cardiomyocyte EVs on inflammasome
activation.
(A) Western blot analysis from whole cell lysates of RAW264.7
macrophage treated with vehicle, H9c2 NTEV, H9c2 DOXEV,
FL83b NTEV, and FL83b DOXEV using an anti-NLRP3, an anti106

caspase-1 or an anti-IL-1 beta antibody. Βeta-actin was used as
loading control. (B-D) Bar graphs represent the average of band
intensities of NLRP3, Caspase-1, and IL-1 beta relative to Actin ±
SD of 3 independent experiments * p < 0.05 vs vehicle, # p < 0.05
vs H9c2 NTEV

Differential effects of H9c2_EVs and FL83b_EVs on reduced thioredoxin 1
(TRX1).
Because TRX1 is a cytosolic redox sensitive protein that can regulate both
NFκB, Nrf-2, and NLRP3 inflammasomes, we further investigated the effect of
EVs on TRX1 in cytoplasm and nuclear fraction of RAW264.7 macrophages in
response to EVs treatment. The purity of cytoplasmic and nuclear fractions was
verified by western blot (Figure 3.8A). Since EVs from cardiomyocytes and
hepatocytes have different levels of protein-bound 4HNE, we hypothesized that
those EVs might have differential effects on the TRX1 redox status, and cause
distinct downstream inflammatory signaling. Our data support this hypothesis.
The TRX1 redox western blots show that H9c2 NTEV-treated macrophages
tended to have lower reduced TRX1 levels in the cytoplasm compared to the
vehicle-treated control and H 9 c2 D O X E V trea tm e nt sig nifica ntly de ple te d
cytoplasmic reduced TRX1. In contrast, FL83b DOXEV significantly increased
the levels of cytoplasmic reduced TRX1. Macrophages treated with FL83b NTEV
also increased cytoplasmic reduced TRX1 but levels did not reach statistical
significance (Figure 3.8B and 3.8D). In the nuclear compartment, only the
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reduced isoform of TRX1 was detected and there is no significant change after
EV treatment (Figure 3.8C and 3.8E). These data suggest that EVs primarily
have an influence on the cytoplasm ic TRX1 redox state rather than in the
nucleus. The depletion of cytoplasmic reduced TRX1 in H9c2 EVs treated cells is
c o n s i s t e n t w i t h NFκB and inflammasome activation, which explains M1
polarization. Low levels of reduced TRX1 is an indicator of cellular oxidative
stress, which might activate Nrf-2 as a defensive response. TRX1 also plays a
crucial role in protein-protein interaction. Under resting conditions, reduced TRX1
binds to its inhibiting partner—thioredoxin interacting protein (TXNIP), which is an
NLRP3 inflammasome activator. The oxidative stress produced by H9c2 EVs
leads to the dissociation of TRX1 from TXNIP allowing TXNIP to activate NLRP3
inflammasomes and subsequent IL-1 beta release.
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Figure 3.8

Differential effects of H9c2_EVs and FL83b_EVs

on reduced thioredoxin 1 (TRX1)
(A) Verification of cytoplasmic and nuclear fraction purification by
western blot of manganese superoxide dismutase (MnSOD) and
beta actin for cytoplasmic fraction, histone deacetylase 1 (HDAC1)
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and lamin A/C for nuclear fraction. (B and C) Redox western of
Trx1 in cytoplasmic fraction (B) and nuclear fraction (C) of
RAW264.7 treated with vehicle, H9c2 NTEV, H9c2 DOXEV, FL83b
NTEV, or FL83b DOXEV. (D and E) Representative bar graph
shows the average fold change (n=3) of reduced Trx1 levels in
cytoplasm (C) and nuclei (D).* p < 0.05 vs vehicle

Discussion
DOX is a potent chemotherapeutic agent that is well known to cause
oxidative stress in normal tissues including the heart and liver. Unfortunately, the
intercellular communication between injured cells and immune cells in response
to oxidative stress during DOX treatment is underinvestigated. Here, we
demonstrate that EVs from heart and liver have different levels of oxidized
molecules and have different effects on macrophage polarization, which is driven
by the redox state of TRX1, and ultimately influences NFκB and Nrf-2 activation.
EVs are released from cells as a compensatory mechanism against
oxidative stress by removing oxidized molecules to maintain cellular homeostasis
[179,180]. Previously, we found that circulating EVs released from normal tissue
targets of DOX are 4HNE-adducted. Moreover, the level of 4HNE adduction in
EVs correlated with the level of tissue oxidative stress [180]. Our finding in the
cell culture system was consistent with the in vivo data, in which EVs that are
released from cardiomyocytes contain higher levels of protein-bound 4HNE than
hepatocyte-derived EVs. This finding is supported by previous literature reporting
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that heart tissue has 150 times less catalase, nearly 4 times less superoxide
dismutase [181], and 27 times less glutathione peroxidase activity [166] than the
liver. As a result, heart is more susceptible to oxidative stress and DOX toxicity
than the liver.
Several lines of evidence show that EVs released during cellular oxidative
stress can regulate the innate immune response. Oxidized components of EVs
such as its lipid membrane, proteins, and nucleic acids turn into DAMPs, which
are recognized by pattern recognition receptors of innate immune cells including
macrophages [74,75]. Here, we found that EVs from cardiomyocytes induced
both M1 and M2 macrophage polarization. Macrophages which express both M1
and M2 phenotypes have been described previously when they have been
challenged with oxidized phospolipids and were called Mox macrophages. Mox
macrophages are a redox-regulating phenotype with a high capacity to withstand
oxidative stress by upregulating anti-oxidant enzymes through Nrf-2 activation
[1 8 2 ]. H o w e ve r, th e N rf-2 c o m p e n sa tio n is in co m p le te so lo w -le v e l o f
inflammation still occurs. Mox macrophages contribute to 30% of macrophages
found in atherosclerotic plaque in mouse model and play a key role in promoting
chronic low-grade inflam m ation [183]. Since we observed that EV s from
cardiomyocytes contains high 4HNE adduction which is an oxidized lipid product,
and since Nrf-2 activation also occurred, we speculated that the macrophage
p h e n o ty p e in d u c e d b y c a rd io m y o c y te E V s w a s M o x. In th is s y s te m ,
cardiomyocytes released highly oxidized EVs and induced a strong innate
immune response without any treatment, which is unlikely to occur in vivo. The
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explanation for this might be that the cells were exposed to 21% O 2 in the cell
culture system, which is much higher than the O2 concentration in tissue (4-14%),
which caused oxidative stress to the cells at baseline [184]. By contrast, this O2
concentration issue is negligible for hepatocytes since they contain plenty of
antioxidant enzymes. When comparing the non-treated and DOX-treated cells,
DOX promoted EV-mediated immunostimulatory effects in cardiomyocytes but
not in hepatocytes. This effect is not due to DOX itself because the drug had
been removed during the washing step. Our in vitro model mimics the clinical
scenario where cardiotoxicity occurs later, after the cessation of DOX treatment.
A low-level but persistent inflammation mediated by Mox macrophages induced
by cardiomycyte-derived EVs could lead to the impairment of cardiac function
and systemic inflammation that can have the effect on indirect targets of DOX
such as brain.
Metabolic reprogramming provides substrates needed for macrophage
function. In our system , m acrophage treatm ent w ith cardiom yocyte EVs
suppressed mitochondrial OXPHOS and promoted glycolysis. Our finding
corresponds with Mox macrophage metabolism where the cells rely more heavily
o n g lu co se m e ta b o lism a n d p e n to se p h o sp h a te p a th w a y ra th e r th a n
mitochondrial respiration. This metabolic shift provides the equivalents required
for antioxidant synthesis to maintain redox homeostasis [185]. Mitochondrial
reserve capacity indicates the ability of mitochondria to respond to oxidative
stress. Hepatocyte EVs promote this capacity and might prevent macrophage
from ROS-mediated cell damage.
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TRX1 is a cysteine reductase enzyme in the cytoplasm that maintains a
reduced state of redox sensitive signaling molecules involved in inflammation.
Overexpression of TRX1 or administration of recombinant TRX1 is protective
against severe inflammatory diseases including inflammatory bowel disease
[186], pancreatitis [61], and sepsis [187]. Here, we demonstrate that TRX1 is a
key protein that regulates macrophage polarization induced by oxidized EVs.
Depletion of the reduced form of TRX1 in cytoplasm as a result of cardiomyocyte
EV treatment might be due to the interaction of TRX1 with oxidized molecules
that are transferred by EV. As a result, TRX1 deficiency could lead to NFκB
activation and inflammasome activation. Lower TRX1 levels cause an imbalance
of cellular redox state, which leads to an adaptive response by enhancing
antioxidant gene expression through Nrf-2 activation.
Consequently, NFκB and Nrf-2 activation drive macrophage polarization to
the intermediate phenotype between M1 and M2. In contrast, hepatocyte EV
induced higher levels of TRX-1 to counteract oxidatively-modified proteins that
are transferred to the cells and can maintain cellular redox state. Therefore,
m acrophages treated w ith hepatocyte EV do not show either M 1 or M 2
polarization (Figure 3.9).
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Figure 3.9

Proposed mechanistic model for the differential

effects of normal tissue-derived EVs in response to DOX
treatment on macrophages
Cardiomyocyte EVs induced M1 and M2 polarization by transferring
4HNE-adducted proteins to the macrophage, which in turn
exacerbates oxidative stress in the macrophage by depleting
reduced cytosolic TRX1. As a result of TRX1 exhaustion, NFκB is
disinhibited and pro-inflammatory cytokines are produced. Nrf-2
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activation occurs as a response to oxidative stress due to TRX1
depletion. DOX aggravates the propagation of oxidative stress by
cardiomyocyte EVs. In contrast, hepatocyte EVs upregulate
cytosolic TRX1 leading to the inhibition of both NFκB and Nrf-2
pathways and make the macrophages remain unactivated. DOX
potentiates the effect of hepatocyte EVs on TRX1 induction thus
preventing macrophage polarization.
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CHAPTER FOUR. CONCLUSION AND FUTURE DIRECTIONS
Conclusion
The results presented in this dissertation demonstrate that extracellular
vesicles

(EVs)

are

early

and

sensitive

biomarkers

for

DOX-induced

cardiomyopathy. After DOX treatment the EVs are not only released from
cardiomyocytes, but also from other direct targets of DOX, such as hepatocytes,
which have a higher antioxidant capacity and lower sensitivity to DOX toxicity.
Functional analysis of EVs released from cardiomyocytes and hepatocytes
reveals that EVs from cardiomyocytes—but not hepatocytes—can propagate
oxidative stress to macrophages by carrying a high level of 4HNE-adducted
proteins that disturb the homeostasis of redox regulators and immunomodulators,
such as thioredoxin (TRX1), leading to macrophage stimulation without any bias
to M1 or M2 polarization. The ability of hepatocyte EVs to upregulate TRX1
makes them non-immunostimulatory. The overall results reveal the role of EVs in
being both biomarkers and mediators of inflammation during DOX treatment.
DOX, along with at least 50% of chemotherapeutic drugs, generate ROS
and/or RNS, leading to oxidative stress and normal tissue injuries that limit the
quality of life for cancer patients. Among the side effects of chemotherapy,
cardiomyopathy is a life-threatening outcome that is a major concern in the clinic.
Despite intensive efforts in the discovery of biomarkers for chemotherapyinduced cardiotoxicity, there is still a lack of sensitive biomarkers that can predict
toxicity early on before the occurrence of cardiac cell death. Since oxidative
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stress is an upstream event of cardiotoxicity, resulting from DOX and EVs being
released in response to oxidative stress, EVs can be a biomarker for oxidative
stress that is detectable before cardiac cell death. Our data support this
speculation, since the amount of EVs as well as the oxidative stress markers—
protein-bound 4HNE—increases before cardiac troponin is detectable. Moreover,
the presence of tissue-specific glycogen phosphorylase (PYGB, PYGM, and
PYGL) in 4HNE-bound EVs confirms that EVs are released from highly oxidized
tissues that are direct targets of DOX. Therefore, EV is a biomarker that links
together oxidative stress markers with tissue-specific markers, making it an ideal
marker for chemotherapy-induced tissue injury.
PYGB has been shown to be an early biomarker for cardiac diseases such
as myocardial ischemia [188,189] and hypertrophic cardiomyopathy [190].
Glycogen phosphorylase (GP) is an enzyme responsible for glycogen
breakdown. Under resting condition, most of the GP is kept dormant (glycogen
phosphorylase b) by the association with sarcoplasmic reticulum (SR)
membranes [191]. The proximity of GP and lipid membranes makes it prone to
4HNE adduction after DOX treatment. 4HNE adduction may prevent the
dissociation of GP from SR membrane and prevent it from being activated. The
inhibition of GP function might affect the ability to utilize glucose from glycogen to
generate ATP and might interfere with the cardiac contraction under stress
condition,

which

could

be

an

early

cardiomyopathy.
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sign

of

chemotherapy-induced

Different organs have different susceptibility of DOX toxicity. Since EV
release is a compensatory mechanism to remove toxic oxidized molecules from
cells under oxidative stress, EVs that are derived from tissues with different
oxidative stress level might have different functions on the recipient cells. The
results from chapter 3 demonstrate that cardiomyocytes with a high sensitivity to
oxidative stress release EVs containing oxidized molecules that activate the proand anti-inflammatory responses of macrophages. In contrast, hepatocytes with
a high tolerance to oxidative stress release EVs that do not have immunological
effects. The function of cardiomyocyte-derived EVs is similar to the effect of
oxidized LDL that promotes atherosclerosis and persistent inflammation [192].
These cytokines can have a local effect on the heart, causing impaired
myocardial contractions [193], and can be distributed to more distant organs.
DOX has been shown to induce the pro-inflammatory release of cytokines into
circulation, including IL-1 beta, TNF alpha, and IL-6 [194]. Prolonged elevation of
inflammatory cytokines is associated with poor treatment outcome, fatigue,
anorexia, and recurring tumors in cancer patients [195]. Moreover, our previous
study found that TNF alpha crosses the blood-brain barrier (BBB) and causes
neurotoxicity known as chemotherapy-induced cognitive impairment [196].
Therefore, inhibiting the effect of oxidized EVs can be a new approach to
preventing inflammatory responses resulting from DOX.
In contrast to cardiomyocyte EVs, hepatocyte EVs enhance TRX1 in
macrophages, suggesting that antioxidant-enriched cells can release EVs to
protect other cells against oxidative stress. TRX1 has been shown to protect
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against atherosclerosis and ischemic/reperfusion injury in mice [197,198].
Treatment with TRX, including recombinant human thioredoxin, TRX-enriched
agents, TRX mimetic agents, or TRX inducers has been proven to be effective
against many inflammatory diseases, including acute pulmonary injury,
pancreatitis, myocarditis, and chronic obstructive pulmonary disease [199].
Based on our results, it is suggested that TRX1 could help to alleviate tissue
injury resulting from inflammation during DOX treatment.
Future Directions
Based on the results in this dissertation, the following experiments may
warrant future investigation:
1.

Could other types of oxidized lipids and proteins become biomarker
candidates?
Since EVs contain different lipid species and different kinds of membrane

proteins, more comprehensive investigations, such as on lipidomics and oxidized
lipid labeling methods coupled with mass spectrometry, should be done to obtain
a complete picture of EV components.
2.

Could EV-associated protein-bound 4HNE and PYGB be used to predict
long-term cardiotoxicity in cancer patients receiving DOX?
Because our study relies on mouse model, the results might not represent

what happens in the clinic. Pre-clinical study in human-derived cardiomyocytes
should be done to confirm the mouse data. Human-derived cardiomyocytes can
119

be obtained from individual patients experiencing DOX-induced cardiomyopathy
by differentiation of their induced pluripotent stem cell in vitro [144]. Studying EVs
from patients-derived cardiomyocytes would provide more precise information
toward clinical application. To really obtain a new biomarker, clinical investigation
should be done on cancer patients receiving DOX, and the patients need to be
followed up long-term.
3.

How long do the EV markers remain in sufficient circulation to be
detectable after DOX treatment?
The major hurdle to long-term screening is the half-life of EVs in

circulation. EVs are more stable than other soluble biomarkers, due to their
protective lipid bilayer. Previous studies have found that the half-life of
endogenous EVs (such as human platelet-derived EVs) in circulation is 5.5 hours
[200]. The clearance is mainly due to the target organ uptake [201]. Therefore,
the detectability of EVs in circulation depends on the rate of production by the
tissue of origin and the rate of uptake by the target organ. Further studies should
be done to evaluate the bioavailability of EVs released from different tissue
sources in long-term DOX treatment.
4.

What is the function of the tissue-specific subpopulation of EVs on normal
macrophages?

Since RAW264.7 cells are virus-transformed peritoneal macrophages,
which are considered leukemic macrophages rather than normal macrophages,
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they might express different sets of pro- and anti- inflammatory cytokines in
response to EV treatment comparing to normal macrophages. Therefore, the
function of EVs in chapter 3 should be confirmed in normal primary macrophages
such as bone marrow-derived macrophages. Eventhough NR8383 cells are
considered normal macrophages, they are still derived from alveoli which locates
away from heart and liver, the two major target organs of DOX. To relate the
function of EVs on innate immune response that leads to DOX-induced tissue
inflammation, cardiac resident macrophages, Kupffer cells, or circulatory
monocytes should be used to confirm the results.

5.

What is the function of the tissue-specific subpopulation of EVs in vivo?
Since all experiments in chapter 3 were done in vitro to study functions of

EVs on two different macrophage cell lines, the data might not represent what
happen in vivo. Therefore, in vivo experiments should be done to confirm the in
vitro study. Such experiments include injection of EVs from non-treated or DOXtreated cardiomyocytes or hepatocytes into normal mice and measure systemic
pro- and anti-inflammatory cytokines. Measurement of reduced and oxidized
forms of TRX1 should be done in bone marrow-derived macrophages isolated
from those mice to confirm the significance of TRX1 in vivo.
6.

Could oxidized EVs pass the blood-brain barrier and affect the central
nervous system (CNS), the same way as soluble cytokine?
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Accumulating evidence has shown that EVs from peripheral blood can
cross the blood-brain barrier into the CNS [202]. The possible mechanism is
mediated by adsorptive-mediated transcytosis, where the cationic molecules are
internalized at the luminal surface of endothelial cells and externalized at the
opposite surface [202]. Therefore, further study should be done to investigate
whether EVs can enter the CNS and affect microglia similar to the effect on the
macrophage.
7.

Could we prevent DOX-induced inflammation by removing oxidized EVs?
Based on our finding that oxidized EVs act in a similar way to oxidized

LDL on the macrophage, further study is warranted to find out if the removal of
EVs (especially 4HNE-adducted EVs) prevents inflammation and systemic
effects on indirect target organs (similar to the effect of lipid-lowering drugs such
as statin). However, since the innate immune response is crucial for anti-tumor
immunity, the prevention of inflammation should be done with caution against
tumor recurrence.
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APPENDICES
APPENDIX A: ACRONYMS
4HNE

4-hydroxynonenal

ALT

alanine transferase

CKMM

creatine kinase isoenzyme MM

cTnI

cardiac troponin I

DOX

doxorubicin

DRZ

dexrazoxane

EVs

extracellular vesicles

GP

glycogen phosphorylase

Hp

haptoglobin

MHC-I

class I histocompatibility antigen

MnP

Mn(III) meso-tetrakis (N-(n-butoxyethyl)pyridium-2yl)porphyrin, MnTnBuOE-2-PyP5+

MnSOD

manganese superoxide dismutase

PYGB

brain/heart glycogen phosphorylase

PYGL

liver glycogen phosphorylase

PYGM

muscle glycogen phosphorylase

RNS

reactive nitrogen species

ROS

reactive oxygen species

SAL

saline

TEM

transmission electron microscopy

TfR1

transferrin receptor 1
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H9c2 EVs

H9c2 cardiomyocyte-derived EVs

H9c2 NTEV

EV from non-treated H9c2 cells

H9c2 DOXEV

EV from DOX-treated H9c2 cells

FL83b EVs

FL83b hepatocyte-derived EVs

FL83b NTEV

EV from non-treated FL83b cells

FL83b DOXEV

EV from DOX-treated FL83b cells

NFκB

nuclear factor kappa-light-chain-enhancer of activated B cells

Nrf-2

nuclear factor (erythroid-derived 2)-like 2

DAMPs

damage-associated molecular patterns

M1 macrophage

pro-inflammatory macrophage

M2 macrophage

anti-inflammatory macrophage

TNFɑ

tumor necrosis factor alpha

IL-1β

interleukin-1 beta

IL-6

interleukin-6

IL-10

interleukin-10

TGFβ

transforming growth factor beta

TRX1

thioredoxin 1

MTT

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
tetrazolium

NO

nitric oxide

IAA

iodoacetic acid

OXPHOS

oxidative phosphorylation

L-NAME

N(G)-Nitro-L-arginine methyl ester
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PRDX-1

peroxiredoxin-1

HO-1

heme oxygenase-1
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APPENDIX B. SOLUTION RECIPE
Cell Culture Media

1. H9c2 growing media
DMEM low glucose
Penicillin/streptomycin
FBS
Non-essential amino acids
HEPES
Sodium pyruvate
Glutamine

2. FL83b growing media
F12K nutrient mixture

Volume

Final concentration

500 ml
5.725 ml

1%

50 ml

10%

5 ml

1%

12.5 ml
10 ml

1 mM

5 ml

2 nM

Volume

Final concentration

500 ml

FBS

50 ml

10%

Penicillin/streptomycin

5.5 ml

1%

5 ml

1%

Volume

Final concentration

Glutamine

3. RAW264.7 growing media
DMEM high glucose
Sodium pyruvate

500 ml
5 ml

1 mM

Glutamine

10 ml

4 mM

FBS

50 ml

10 %
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Penicillin/streptomycin

4. NR8383 growing media
Ham’s F12K medium
Glutamine

5.6 ml

1%

Volume

Final concentration

500 ml
5 ml

2 mM

Sodium bicarbonate

12 ml

1.5 g/L

Heat inactivated FBS

90 ml

15 %

Penicillin/streptomycin

6.1 ml

1%
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Buffer and Reagents

1. Running buffer (10x)

Volume

Tris base

12.1 g

Glycine

38.45 g

10% SDS

40 ml

dH2O

400 ml

To make 1x running buffer, dilute 100 ml of 10x running buffer in 900 ml of
dH2O.

2. Transfer buffer (10x)

Volume

Glycine

144 g

Tris base

30 g

dH2O

up to 1 L

To make 1x transfer buffer

Volume

10x transfer buffer

100 ml

dH2O

700 ml

methanol

200 ml

3. TBST (Western blot wash buffer)
3 M Tris-HCL pH 7.5

Volume
13.3 ml
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5 M NaCl

66 ml

0.5 M EDTA

4 ml

Tween-20

1 ml

dH2O

up to 2 L

4. G-lysis buffer (6 M)

Volume

Guanidine.HCl

57.32 g

EDTA

96.20 mg

Tris base

788 mg

Triton X-100

0.5 ml

dH2O

up to 100 ml

Adjust pH to 8.3 with 10 M NaOH

5. G-lysis buffer with 50 mM IAA

Volume

G-lysis buffer

5 ml

IAA

46.5 mg

Prepare solution fresh before protein derivatization
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6. Hypotonic buffer

Volume

HEPES

119 mg

KCL

37.3 mg

MgCl2

9.5 mg

EDTA

1.87 mg

NaF

0.42 mg

Na3VO4

1.84 mg

dH2O

up to 50 ml

7. Native and non-reducing sample loading buffer (5x)
1 M Tris.Cl, pH 6.8

3.1 ml

Glycerol

5 ml

1% (w/v) bromphenol blue

0.5 ml

dH2O

1.4 ml

8. Native polyacrylamide separating gel, 15% (2 gels)
30% polyacrylamide/0.8% bis

8 ml

1.5 M Tris.Cl, pH 8.8

3.2 ml

dH2O

3.84 ml

1.5% ammonium persulfate

0.8 ml

TEMED

10 μl
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Pour immediately into the gel frame and allow it to polymerize

9. Native polyacrylamide stacking gel, 6% (2 gels)
30% polyacrylamide/0.8% bis

1 ml

0.5 M Tris.Cl, pH 6.8

1 ml

dH2O

1.85 ml

1.5% ammonium persulfate

0.6 ml

TEMED

5 μl

Pour the gel immediately and allow it to polymerize

10. Native running buffer, 10x

Volume

Tris base

30 g

Glycine

144 g

dH2O

up to 1 L

Store up to 6 months at room temperature
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